

## REVIEW

# Revisiting the role of melatonin in human melanocyte physiology: A skin context perspective

Alec Sevilla<sup>1</sup>  | J  r  my Ch  ret<sup>1</sup>  | Radomir M. Slominski<sup>2,3</sup>  | Andrzej T. Slominski<sup>3,4</sup>  | Ralf Paus<sup>1,5,6</sup> 

<sup>1</sup>Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA

<sup>2</sup>Graduate Biomedical Sciences Program, University of Alabama at Birmingham, Birmingham, Alabama, USA

<sup>3</sup>Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA

<sup>4</sup>Pathology Laboratory Service, Veteran Administration Medical Center at Birmingham, Birmingham, Alabama, USA

<sup>5</sup>Monasterium Laboratory, M  nster, Germany

<sup>6</sup>CUTANEON—Skin & Hair Innovations, Hamburg, Germany

## Correspondence

Andrzej T. Slominski, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Email: [aslominski@uabmc.edu](mailto:aslominski@uabmc.edu)

Ralf Paus, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA.

Email: [rxp803@med.miami.edu](mailto:rxp803@med.miami.edu)

## Funding information

VA merit grant; NIH grants; Frost Endowed Scholarship

## Abstract

The evolutionarily ancient methoxyindoleamine, melatonin, has long perplexed investigators by its versatility of functions and mechanisms of action, which include the regulation of vertebrate pigmentation. Although first discovered through its potent skin-lightening effects in amphibians, melatonin's role in human skin and hair follicle pigmentation and its impact on melanocyte physiology remain unclear. Synthesizing our limited current understanding of this role, we specifically examine its impact on melanogenesis, oxidative biology, mitochondrial function, melanocyte senescence, and pigmentation-related clock gene activity, with emphasis on human skin, yet without ignoring instructive pointers from nonhuman species. Given the strict dependence of melanocyte functions on the epithelial microenvironment, we underscore that melanocyte responses to melatonin are best interrogated in a physiological tissue context. Current evidence suggests that melatonin and some of its metabolites inhibit both, melanogenesis (via reducing tyrosinase activity) and melanocyte proliferation by stimulating melatonin membrane receptors (MT1, MT2). We discuss whether putative melanogenesis-inhibitory effects of melatonin may occur via activation of Nrf2-mediated PI3K/AKT signaling, estrogen receptor-mediated and/or melanocortin-1 receptor- and cAMP-dependent signaling, and/or via melatonin-regulated changes in peripheral clock genes that regulate human melanogenesis, namely *Bmal1* and *Per1*. Melatonin and its metabolites also accumulate in melanocytes where they exert net cyto- and senescence-protective as well as antioxidative effects by operating as free radical scavengers, stimulating the synthesis and activity of ROS scavenging enzymes and other antioxidants, promoting DNA repair, and enhancing mitochondrial function. We argue that it is clinically and biologically important to definitively clarify whether melanocyte cell culture-based observations translate into melatonin-induced pigmentary changes in a physiological tissue context, that is, in human epidermis and hair follicles *ex vivo*, and are confirmed by clinical trial results. After defining major open

questions in this field, we close by suggesting how to begin answering them in clinically relevant, currently available preclinical in situ research models.

#### KEYWORDS

hair follicle, human skin, melanocyte, melatonin, pigmentation

## 1 | INTRODUCTION

The ancient amphipathic indolamine, melatonin, which is believed to exist in all living organisms on Earth,<sup>1,2</sup> not only is the key neurohormone that regulates the circadian clock<sup>3</sup> and antioxidant activities,<sup>4,5</sup> but also an astonishingly versatile molecule with a plethora of other complex biological functions<sup>6–8</sup> (Table 1). Dermatologist Aaron B. Lerner discovered melatonin as the active molecule that exerts potent skin lightening effects on amphibian melanophores.<sup>54</sup> Since then, melatonin has long captured the attention of skin biologists and investigative dermatologists for its multitude of documented activities, many of which are relevant to human skin physiology and pathology, ranging from antiaging,<sup>10,55–57</sup> UV-protection,<sup>28,58–60</sup> immunomodulation,<sup>31,32</sup> and antimelanoma activity<sup>16,17,61</sup> to potential hair growth-promoting<sup>62,63</sup> and pigmentation-modulatory effects.<sup>63–65</sup>

Yet, it remains unclear how exactly intracutaneously synthesized melatonin impacts on human skin and hair follicle (HF) pigmentation in situ and in vivo, how it affects other human melanocyte functions, and whether it protects these melanocytes from damage and/or senescence in situ. Even less is known about the relative contribution of insufficient melatonin synthesis and/or melatonin receptor expression in human skin in the context of melanocyte and skin pathology. Moreover, it is not yet entirely clear which of melatonin's receptors or pathways mediate each of its functional effects in human skin, which receptors/pathways are involved in its modification of mitochondria and cellular metabolism, or which nuclear receptors are plausible candidates for its bioregulation. To a considerable extent, this may be owed to the fact that the bulk of published melatonin studies have utilized cell culture methodology or animal models, while human skin and HF organ culture has been under-employed, even though these assays would have been most instructive from a physiological perspective. Additionally, melatonin's mechanisms of actions in human skin are very complex and have not been dissected as systematically as desired, perhaps due to few investigative dermatologists conducting such research in the past decades, limited industry and NIH funding, and challenging requirements (e.g., ethical rules and IRB approval) for conducting experiments with humans.

Therefore, the current review re-explores the role of melatonin in human melanocyte physiology. We argue that it is timely and both clinically important and biologically instructive to now clarify definitively whether the previously reported observations regarding melatonin's effects on isolated human melanocytes in vitro (see below) really translate to a human tissue context, that is, where melanocyte activities are closely controlled by their intimate interactions with epidermal or HF keratinocytes within the epidermal<sup>64,66,67</sup> or HF pigmentary unit (EPU or HFPU).<sup>68–70</sup>

This tissue context-perspective on human melanocyte biology is critically important, but too often ignored. Besides several pigmentation-regulatory growth factors, cytokines, and eicosanoids, keratinocytes produce and secrete major pigmentation-stimulatory neurohormones, such as  $\alpha$ -melanocyte-stimulating hormone (MSH), adrenocorticotropin (ACTH), corticotropin-releasing hormone (CRH), and thyroid-releasing hormone (TRH)<sup>16,17,31,32,61,71</sup> and rigorously control melanocyte functions through interactions with corresponding G-protein-coupled receptors<sup>64,72,73</sup> and by regulating E- and P-cadherin expression on their cell surface.<sup>74,75</sup>

With recent insights into the impact of neurotransmitters (e.g., acetylcholine) released by sympathetic nerve fibers innervating the bulge, as in murine HF melanocyte stem cells,<sup>76</sup> a tissue context-dominated perspective on examining the role of melatonin in human pigmentation and melanocyte physiology has become even more important, but also more complex. Such a tissue context perspective must include the skin mesenchyme, since additional inputs on pigmentation originate from dermal fibroblasts in the human EPU,<sup>72,73</sup> inductive fibroblasts in the HF's dermal papilla, and perifollicular dermal white adipose tissue which secrete HFPU- and melanogenesis-stimulatory hepatocyte growth factor.<sup>77,78</sup> These mesenchymal inputs rhythmically switch HF pigmentation on and off in a strictly hair cycle-dependent manner, with induction of HF melanocyte apoptosis during each phase of HF regression (catagen) and reconstruction of a new HFPU during each re-entry into the phase of active hair growth (anagen) from resident progenitor cells.<sup>69,79</sup> This dramatic remodeling of the HFPU, the cyclic mesodermal-neuroectodermal interactions that govern it, and the

**TABLE 1** A selection of recognized melatonin functions

Melatonin functions: Examples	References
Aerobic glycolysis inhibition (glycolytic)	9
Antiaging	10–12
Anti-inflammatory	13–15
Antimelanoma: antiproliferative and anti-invasive effects	16–19
Antineoplastic: antiproliferative and cell cycle arrest	20
Antioxidant	21,22
Blood pressure regulation	23
Body mass regulation	24
Bone mass regulation	25,26
Cardioprotection	23,27
Circadian rhythm regulation	3,6
DNA repair	28
Dopaminergic neuron development in the substantia nigra	29
Estrogen receptor regulation	30
Gastrointestinal tract protection	26
Immune cell proliferation and cytokine release	31,32
Inner ear protection	33
Insulin secretion regulation	34
Liver disease protection	35
Mitochondrial function and biogenesis	36
Nephroprotection	37
Neuroprotection	38
Retina protection	39,40
Reproduction and sexual maturation regulation	41,42
Sensitization of cancers to radiation and chemotherapy	43–47
UV protection	21,48–52
Wound healing	53

rhythmic extrapineal synthesis of melatonin within human HFs<sup>30</sup> make the HFPU a fascinating and instructive model system for exploring the impact of melatonin on the complex controls of human hair pigmentation, which contrasts against the much less dynamic, constantly active EPU. This also illustrates why one cannot expect to recreate such a complex and dynamic cell-cell interaction system in melanocyte cell culture.


Importantly, melatonin and its precursors, serotonin and N-acetylserotonin (NAS), are synthesized within mammalian skin,<sup>60,80–82</sup> explicitly also in human skin,

HFs, and resident cell populations of human epidermis or dermis.<sup>82,83</sup> Furthermore, the entire biochemical machinery necessary for transforming L-tryptophan into melatonin is expressed in all main tissue compartments of human skin, by epidermal and HF keratinocytes and melanocytes, dermal fibroblasts, and even mast cells.<sup>60,83–85</sup>

Since melatonin synthesis, metabolism, signal transduction (Figure 1), target genes, and mechanisms of action have been extensively reviewed elsewhere,<sup>86,96–99</sup> it suffices to summarize here some salient features. Melatonin is synthesized in a multistep process from tryptophan<sup>99</sup> in the pineal gland and numerous “nonclassical,” extrapineal tissues in the human body such as skin and HFs (see below),<sup>63,73</sup> also in intact, wild-type rodent (including mice) skin.<sup>58</sup> While one key step in the classical (intrapineal) pathway of melatonin synthesis involves the conversion of serotonin to NAS (obligatory precursor to melatonin) by aralkylamine N-acetyltransferase (AANAT), there exists an alternative pathway operating in peripheral organs, such as that found in the AANAT-mutant C57BL/6 mouse strain.<sup>100</sup> Serotonin within C57BL/6 mice skin can instead be acetylated to NAS by arylamine N-acetyltransferase (NAT),<sup>100</sup> which can then be transformed to melatonin by the enzyme common to both classical and alternative pathways, hydroxyindole-O-methyltransferase (HIOMT).<sup>82</sup> Therefore, it is misleading to characterize C57BL/6 mice as a “natural melatonin knockdown” species.<sup>30,58,100</sup>

Due to melatonin's amphiphilic nature, it can readily penetrate any cell, tissue, and cellular compartment.<sup>101–104</sup> Here, melatonin exerts its complex effects dependent on the expression, localization, and types of melatonin receptors involved,<sup>105,106</sup> that is, the cell membrane-bound, G-protein coupled MT1 and MT2 receptors, and on several membrane-bound receptor-independent mechanisms<sup>107</sup> (Figure 1). It has been clarified that melatonin and its metabolites are not ligands for the nuclear receptor retinoid-related orphan receptor- $\alpha$  (ROR- $\alpha$  aka NR1F1), as shown by crystallography studies,<sup>108,109</sup> modeling and receptor functional assays.<sup>110</sup> However, melatonin may indirectly modulate ROR- $\alpha$  and other ROR activities.<sup>109,111</sup>

Moreover, facilitated by their dendritic morphology, which greatly augments their cell surface and thus contact area, melanocytes operate as multimodal sensory and stress-response cells.<sup>112–116</sup> Melanocytes also engage in bidirectional communication with their tissue-specific intraepithelial habitat,<sup>112</sup> for example, by secreting catecholamines, cytokines, eicosanoids, acetylcholine, melanocortins, ACTH, CRH, endorphins, enkephalins, nitric oxide, serotonin, and reactive oxygen species (ROS) produced during melanogenesis.<sup>60,81,117–130</sup> Thus,



**FIGURE 1** Schematic summary of melatonin's effects in human epidermal and HF melanocytes. Exogenous or endogenously synthesized melatonin can regulate phenotype in these cells through interactions with membrane-bound MT1/2 receptors NQO2, and the calcium/calmodulin complex or through stimulation of Nrf2 (reviewed in Slominski et al.<sup>86</sup>). However, it is not fully understood if melatonin activates NQO2, a detoxifying enzyme.<sup>7,87,88</sup> Noteworthy phenotypic effects of melatonin include melanogenesis inhibition, and stimulation of DNA repair, and expression and activity of antioxidant enzymes (e.g., superoxide dismutase and catalase) (reviewed in Slominski et al.<sup>8</sup>). Melatonin may also be transported to different subcellular compartments, but the detailed mechanism is not fully understood.<sup>63</sup> Furthermore, melatonin can be synthesized within these melanocytes. Melatonin and its metabolites, such as cyclic-3-hydroxymelatonin (C-3HOM) and N-acetyl-5-methoxykynuramine (AMK), directly scavenge ROS/RNS<sup>89,90</sup> and help maintain mitochondrial homeostasis through interactions with cytochrome C and enzymes of the ETC. Specifically, cytochrome C within mitochondria is thought to be involved in the conversion of melatonin to its potent antioxidant metabolite, N(1)-acetyl-N(2)-formyl-5-methoxykynuramine (AFMK),<sup>91</sup> and its secondary product, AMK, when in the presence of hydrogen peroxide.<sup>92</sup> Also, melatonin may interact with cytochrome C and ETC enzymes within mitochondria to promote mitochondrial homeostasis and decrease free radical formation.<sup>93</sup> Furthermore, melatonin may affect the transcription of peripheral clock genes *Bmal1* and *Per1* with alterations in melanogenesis and other melanocyte activities.<sup>65,94,95</sup> Direct effects are shown by solid lines and multiple reactions and signaling are shown by dashed lines. ETC, electron transport chain; HF, hair follicle; MT1/2, melatonin receptors 1 and 2; NQO2, N-ribosyldihydronicotinamide:quinone reductase 2; Nrf2, nuclear factor erythroid 2-related factor 2; RNS, reactive nitrogen species; ROS, reactive oxygen species

melanocytes contribute actively to shaping the signaling and metabolic milieu they reside in.<sup>113,115</sup> Transfer of melanosomes into keratinocytes likely promotes keratinocyte terminal differentiation and other functions.<sup>72,84,85</sup> Recently, aging melanocytes have even been reported to act as drivers of epidermal senescence.<sup>131</sup>

Taken together, the crucial tissue context in which melanocytes operate renders it impossible to fully grasp how melatonin regulates human pigmentation under mere cell culture conditions, even when primary human

melanocytes are cocultured with selected isolated other cell populations, since even such coculture system cannot recapitulate the complexity of physiological interactions between neural crest-derived, epithelial and mesenchymal cells that control pigmentation in situ.<sup>112–114</sup>

This review synthesizes the currently available evidence regarding melatonin's effect on melanogenesis, oxidative biology and damage responses, senescence, and peripheral clock genes in the wider context of human



melanocyte physiology within their cutaneous habitat. These include conditions of excessive oxidative stress, which underly melanocyte pathology, for example, in vitiligo<sup>132,133</sup> and hair graying.<sup>68,134,135</sup> We define major open questions, suggest how to answer them using currently available preclinical assay systems, and discuss the clinical relevance of systematically characterizing the role of melatonin in human melanocyte function in health and disease from a tissue context perspective.

## 2 | SKIN AS A TARGET AND SOURCE OF MELATONIN BIOACTIVITY

Human skin possesses all key enzymes, substrates, and cofactors necessary for melatonin synthesis,<sup>81,82</sup> and melatonin synthesis in human scalp HFs *ex vivo* is stimulated by noradrenaline, just as in the pineal gland.<sup>30</sup> Given that this key psychoemotional stress-associated neurotransmitter can promote the depletion of melanocytes stem cells from their niche in murine HFs,<sup>76</sup> one wonders whether noradrenaline-induced upregulation of HF melatonin synthesis simultaneously activates melatonin-dependent cytoprotective mechanisms (see below). Importantly, both keratinocytes and melanocytes of the EPU can also synthesize catecholamines<sup>136,137</sup> and thereby could, in theory, augment their own melatonin synthesis in an autocrine and paracrine manner, possibly in response to local tissue stressors.

Human skin and HFs also are important targets of melatonin bioactivity and express melatonin receptors (MT1/2).<sup>97,121,138</sup> Animal studies involving pinealectomy or melatonin administration have demonstrated changes in HF growth, cycling, and pigmentation (Table 2). The latter has raised the question of how exactly melatonin affects human epidermal and HF melanocytes<sup>60,62,79</sup> within their natural tissue habitat, rather than in culture isolated from their key communications with epidermal and HF keratinocytes, papillary dermal fibroblasts,<sup>167</sup> and HF dermal papilla fibroblasts.<sup>68,69</sup> Yet, dissecting how exactly endogenous melatonin alters human melanocyte biology *in situ* is challenged by melatonin's complex interactions and rapid metabolism,<sup>92,168</sup> which make it exceptionally difficult to dissect precisely which phenotypic effects are regulated by melatonin itself versus its many metabolites, as well as by differential effects dependent on dose, cellular and hormonal environment, tissue, species, gender, age, race, and external (environmental) and internal stress levels.<sup>48,62,169,170</sup> Therefore, the results from *in vitro* and animal studies on the pigmentary impact of melatonin could be misleading as they cannot fully reflect the human *in vivo* condition. It is for this reason that we

advocate the use of standardized, site- and gender-specific human skin, and HF organ culture models to definitively clarify the effects of melatonin on human skin pigmentation in UV-exposed versus nonexposed skin.

## 3 | CLINICAL POINTERS

Clinical observations provide important pigmentary background information when interpreting *in vitro* and animal results under melatonin administration. Few studies have examined the effects of melatonin on pigmentation in humans without pigmentary disorders. In both former- and never-smoker postmenopausal women who received microdermabrasion, neither oral (2.5 mg/day) nor topical (0.5 mM) melatonin had significant effects on skin pigmentation.<sup>171</sup> Another pilot study saw no effects of oral melatonin on arm, leg, or back skin pigmentation of seven subjects.<sup>172</sup> This could have resulted from an insufficiently short observation period or the rapid metabolism of orally delivered melatonin upon liver passage.

There is an extreme scarcity of any documented potential cutaneous effects from the extensive ingestion of melatonin. This, in part, is likely best explained by ingested melatonin's extensive and rapid metabolism during its first pass through the liver, where it is rapidly hydroxylated to 6-hydroxymelatonin with further sulfation or glucuronidation before reaching the skin. These biochemical modifications minimize the impact of orally administered melatonin on human skin function. Therefore, to see the cutaneous effects of melatonin, it is best for it to be synthesized *in situ* or applied topically.

Very few studies have investigated melatonin effects on human pigmentation disorders. In one patient with adrenal hyperplasia-associated diffuse skin hyperpigmentation, a month of high-dose (1 g/day) oral melatonin decreased skin pigmentation, yet failed to alter skin pigmentation in three other patients with idiopathic hyperpigmentation and one patient with Addison's disease.<sup>173</sup> In a small cohort of patients with acanthosis nigricans, oral melatonin (3 mg/day) reportedly reduced hyperpigmentation.<sup>174</sup> In patients with melasma, topical (5% cream) and oral (3 mg/day) melatonin reportedly showed significant skin-lightening effects.<sup>175</sup> Other studies also reported decreased skin pigmentation and enhanced protection against photoaging after topical melatonin.<sup>28,63,176,177</sup> These limited clinical observations suggest that melatonin may exert (direct or indirect) melanogenesis-inhibitory activities in human epidermis *in vivo*, yet conclusive evidence remains to be provided.

Interestingly, patients with vitiligo had significantly lower immunohistochemically assessed melatonin-associated immunoreactivity in both lesioned and

TABLE 2 Effects of melatonin on hair growth and pigmentation

Species	Effect	References
<i>Growth</i>		
Mouse	Influence on the hair cycle by the pineal gland	139
Weasel	Induction of molt	140
Mink	Induction of autumn molt	141
Soay rams	Stimulation of molting	142
Limousine ram	Increased HF activity and reduced prolactin plasma levels	143
Mink	Induction of winter fur growth (supposedly by inhibition of prolactin)	144
Cashmere goat	Increase of growth initializing activity of secondary HFs in springtime	145
Red deer	Premature molting of summer pelage and reduced serum prolactin concentrations	146
Merino sheep	No influence of pinealectomy on wool growth and hair density	147
New Zealand goat	Induction of pro-anagen phase	148
Cashmere goat (cultured HFs)	Increase of hair shaft elongation and DNA-synthesis	149
Domestic pig	Increase of pelage development and cycle frequency	150
Ferret	Earlier change of winter and consecutive spring coat	151
Raccoon dogs	More rapid shedding of mature underfur hairs and growth of new underfur hairs; suppression of prolactin levels	152
Siberian Husky dogs	No change in hair growth or anagen rate (topical administration)	153
Rex Rabbit offspring	Maternal melatonin supplementation increased HF density, reduced hairiness, and improved fur quality of offspring	154
Cashmere goat	Continuous subcutaneous implantation of melatonin promoted cashmere to enter the anagen 2 months earlier and induce secondary hair follicle development	155
Human (cultured HFs)	Increase of hair shaft elongation (30 $\mu$ M); Decrease of hair shaft elongation (1–5 mM)	156
Human (cultured HFs)	No influence on hair shaft elongation, matrix keratinocyte proliferation/apoptosis and hair cycling ( $10^{-12}$ – $10^{-6}$ M)	30
Human (trichograms)	Slight increase of anagen hair rate in women with androgenetic and diffuse alopecia	157
Human (clinical assessment)	Topical melatonin loaded in antioxidant nanostructured lipid carriers significantly increased hair density and hair shaft diameter when compared to topical melatonin alone in men with androgenetic alopecia	158
<i>Pigmentation</i>		
Weasel	Induction of hair color change	140
Mammalians	Effects on hair color	159
Djungarian hamster	Pattern of melatonin release induced by experimentally induced photoperiods modifies molt into summer pelage	160
Siberian hamster (cultured HFs)	Post-tyrosinase inhibition of melanogenesis ( $10^{-10}$ – $10^{-6}$ M)	161
Yellow mice (C3H/He-A*vy)	Slight reduction of coat darkening	162
Mountain hares	Season-dependent effects of melatonin on fur color	163
Djungarian hamster	Induction of the winter molt and pelage color change	164
Djungarian hamster	Change of fur color	165
Mouse	Inhibition of melanogenesis	166
Human (cultured HFs)	No effect on pigmentation ( $10^{-12}$ – $10^{-6}$ M)	30

Abbreviation: HF, hair follicle.

non-lesioned skin when compared to skin of healthy controls, suggesting a role for melatonin deficiency in the pathogenesis of vitiligo.<sup>178</sup> However, serotonin, 5-hydroxyindoleacetic acid (5-HIAA) and melatonin serum levels have been reported to be increased in a relatively small cohort of vitiligo patients.<sup>179</sup> Yet, the pathobiological significance and therapeutic potential of melatonin in vitiligo<sup>180</sup> remains unexplored and requires systematic additional investigation.

Serum melatonin levels decline with age,<sup>55</sup> which may contribute to the slow decline of organ function characteristic of aging.<sup>11</sup> Thus it is conceivable that a gradual loss of melatonin in aged or graying HFs along with an age-dependent accumulation of oxidative damage in the HFPU and correspondingly reduced oxidative damage protection of HF melanocytes by both systemic and intrafollicularly produced melatonin levels contributes to hair graying.<sup>68</sup>

## 4 | DIRECT IMPACT OF MELATONIN ON MELANOGENESIS

### 4.1 | Melatonin and its metabolites tend to inhibit melanogenesis, tyrosinase activity, and/or melanocyte proliferation in vitro

In normal human epidermis, melatonin and its metabolites, for example, N1-acetyl-5-methoxykynuramine (AMK), N(1)-acetyl-N(2)-formyl-5-methoxykynuramine (AFMK), 6-hydroxymelatonin (6-OHM), and 5-methoxytryptamine (5-MT), accumulate in vivo.<sup>170,181</sup> In human epidermal melanocytes in vitro, melatonin and its metabolites inhibit melanocyte proliferation<sup>170</sup> and some<sup>170</sup> but not all<sup>181</sup> metabolites inhibit melanogenesis by decreasing tyrosinase activity. Of all melatonin's metabolites, 6-OHM showed the greatest inhibition (50%) of tyrosinase activity in normal human epidermal melanocytes in vitro.<sup>170</sup> In contrast, melatonin and its metabolites had no effect on melanogenesis in human SKMEL-188 melanoma cells, except for 5-MT (at 10  $\mu$ M) which even stimulated melanogenesis.<sup>170</sup> Yet, in another human melanoma cell line, MNT-1, melatonin inhibited melanin production at high doses (1, 100, and 1000  $\mu$ M).<sup>182</sup>

Interestingly, in rodent melanoma cells, melatonin at low concentrations (0.1–10 nM) inhibited melanocyte proliferation but had no effect on melanogenesis, while at high concentrations ( $\geq 0.1$   $\mu$ M) it inhibited the induction of melanogenesis and tyrosinase activity but not proliferation.<sup>17</sup> Similarly high doses of melatonin were required to inhibit anagen-associated tyrosinase activity


in histocultured skin from C57BL-6 mouse, and two high- and low-affinity binding sites were detected in crude skin extracts.<sup>166</sup> These are consistent with high doses of melatonin required for phenotypic effects in normal human epidermal melanocytes.<sup>170</sup>

Thus, melatonin's effects on melanogenesis and melanocyte proliferation appear to be rather variable, dependent on dose, tissue type, species, and signaling environment.<sup>48,62</sup> This further underscores that understanding the physiological and pharmacological responses of human melanocytes to melatonin stimulation is best studied in a full-thickness human skin or HF organ culture (ex vivo) or in vivo, rather than in cultured isolated melanocytes (in vitro).

### 4.2 | Mechanisms of melatonin regulation of human melanogenesis

Besides targeting its specific membrane receptors on melanocytes, in human skin, several indirect or nonclassical mechanisms by which melatonin may regulate melanogenesis deserve consideration. For example, melatonin can downregulate estrogen receptor expression in mouse HFs,<sup>30</sup> which could antagonize 17- $\beta$ -estradiol's stimulatory effects on melanogenesis.<sup>183</sup> However, at  $\leq 1$   $\mu$ M melatonin did not inhibit intrafollicular melanin synthesis in organ-cultured human anagen VI scalp HFs.<sup>30</sup> Of note, anti-melanogenic activity of melatonin in rodent melanomas and murine skin organ culture required higher than 1  $\mu$ M concentration to observe the phenotypic effect.<sup>17,166</sup>

Though ROR is no longer a credible direct nuclear hormone receptor for melatonin, an indirect modulation of ROR signaling activity by melatonin which could impact melanogenesis remains theoretically conceivable.<sup>109</sup> Additional indirect mechanisms of action must also be considered. The observed melanogenesis inhibition by melatonin in Siberian hamster HF melanocytes appears to have antagonized the pigmentation-promoting effects of  $\alpha$ -MSH,<sup>184</sup> likely by reducing expression of cognate  $\alpha$ -MSH receptors (MC-1R), as described in mouse melanoma cells,<sup>185</sup> and/or counteracting the promotion of melanogenesis by  $\alpha$ -MSH or L-tyrosine (based on in vitro data from hamster and murine melanoma cells).<sup>17</sup> Since specific binding of tritiated-melatonin to the purified membrane and nuclei melanocyte fractions were detected,<sup>17,166</sup> the antiproliferative effect of melatonin was proposed to be mediated through interaction with MT receptors, while the melanogenesis-inhibitory effect might involve interaction with a putative nuclear receptor.

**(Normal human epidermal melanocytes)**

**FIGURE 2** Schematic summary describing PI3K/AKT pathway modulation and its effects on melanogenesis. In normal human melanocytes, melatonin stimulates Nrf2,<sup>28</sup> which can activate the PI3K/AKT pathway to phosphorylate (i.e., inactivate) GSK-3. Without GSK-3, MITF remains unphosphorylated (i.e., inactive), leading to decreased transcription of tyrosinase, TRP-1, and TRP-2, thereby decreasing melanogenesis<sup>94</sup>

In normal human epidermal melanocytes, the central regulator of oxidative damage responses, nuclear factor erythroid 2-related factor 2 (Nrf2),<sup>186,187</sup> is targeted by melatonin to upregulate antioxidant defenses,<sup>28</sup> but decreases melanogenesis through a pathway involving activation of PI3K/AKT. Activated PI3K/AKT signaling leads to inactivation of glycogen synthase kinase-3 (GSK-3) and microphthalmia-associated transcription factor (MITF), which inhibits the transcription of *TYR*, *TRP-1*, and *TRP-2* (melanogenesis-associated enzymes) and decreases melanin synthesis<sup>94</sup> (Figure 2). Thus, it is conceivable that melatonin may inhibit melanogenesis in normal human epidermal melanocytes also through activation of Nrf2 and subsequent activation of the PI3K/AKT pathway.

## 5 | MELATONIN, OXIDATIVE STRESS, AND THE MELANOCYTE ECOSYSTEM

### 5.1 | Melatonin and its metabolites regulate antioxidant enzyme expression and direct free radical scavenging

Melatonin and its metabolites (e.g., cyclic-3-hydroxymelatonin [C-3HOM] and AMK)<sup>188</sup> are powerful direct scavengers of ROS and reactive nitrogen species (RNS)<sup>89,90</sup> that protect human melanocytes from oxidative damage.<sup>28</sup> Moreover, once melatonin binds to MT1/2 receptors, the downstream signaling cascade stimulates the expression of numerous antioxidant enzymes<sup>89,189</sup> (Figure 3). These properties of melatonin may play a key role in maintaining skin<sup>28</sup> and HF<sup>192</sup> pigmentation, given that melanogenesis itself is a cytotoxic process that generates ROS and quinone and semiquinone compounds, which are buffered by melanin itself as well as by other mechanisms.<sup>193–195</sup>

Furthermore, melatonin can activate Nrf2, a transcription factor regarded as the master regulator of antioxidant defenses (e.g., defense against ultraviolet [UV] B radiation-induced oxidative skin damage),<sup>28</sup> in part by upregulating its expression in human epidermal


melanocytes. Nrf2 is also significantly upregulated in response to oxidative stress in human anagen HF, namely in the HFPU.<sup>196</sup> Interestingly, the melatonin-induced activation of Nrf2 in human epidermal melanocytes exposed to oxidative stress occurs independently of melatonin receptors,<sup>28</sup> possibly by regulating the Keap/Nrf2/ARE pathway and suppressing the ubiquitin/proteasome system, thereby increasing Nrf2-ARE activation and expression and activity of antioxidant enzymes.<sup>1,11</sup> Furthermore, Nrf2-ARE activation is necessary for protecting human epidermal melanocytes from hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-induced oxidative stress,<sup>197</sup> either by metabolically eliminating ROS or by reducing their generation,<sup>1</sup> thereby preventing DNA damage and premature senescence.<sup>10,28</sup>

Melatonin's activation of NQO2, a detoxifying enzyme that directly reduces H<sub>2</sub>O<sub>2</sub> and dangerous quinones, is another means of defense against oxidative stress,<sup>190,191</sup> which has not yet been identified in human HF melanocytes. However, NQO2 gene expression occurs widely in human skin,<sup>7,48</sup> including epidermal melanocytes<sup>28</sup> and microarray data point towards its expression in murine HF.<sup>198</sup> Also, intracellular melatonin at concentrations higher than 1 nM interacts with the calcium/calmodulin complex, which inhibits nitric oxide synthase 1 (NOS1 or nNOS) and its generation of RNS.<sup>86,199–201</sup> Furthermore, melatonin and its metabolites protect human epidermal melanocytes from UV-B-induced damage/apoptosis (see Section 5.3) by enhancing p53-stimulated DNA repair.<sup>28</sup> The discussed antioxidant mechanisms of melatonin and its metabolites are described in further detail in Figure 3.

### 5.2 | Decreased melatonin levels related to aging- or oxidative stress-related hair graying

Loss of human hair pigmentation (e.g., aging- or stress-related graying) is thought to primarily result from oxidative damage that disrupts differentiated HF melanocytes of the HFPU and melanogenesis-related enzymes, with subsequent damage to HF melanocyte stem cells,





**FIGURE 3** Schematic summary describing antioxidant defense mechanisms by melatonin and its metabolites in human melanocytes. Melatonin can bind to MT1 and MT2 receptors on the cell membrane, triggering a signaling cascade that leads to the expression of antioxidant enzymes (e.g., SOD, GPx, GR, and CAT) for defense against ROS and RNS.<sup>89,189</sup> Melatonin may also be transported to the cytoplasm, but the detailed mechanism is not fully understood.<sup>63</sup> Furthermore, melatonin can be synthesized within these melanocytes. Melatonin and its metabolites, such as C-3HOM and AMK, can directly scavenge ROS/RNS.<sup>89,90</sup> Furthermore, melatonin and its metabolites, including AFMK, 6-OHM, 5-MT, and NAS, protect human epidermal melanocytes from UV-B-induced damage/apoptosis by enhancing phosphorylation of p53 at Serine 15, thereby leading to activated p53 accumulation in the nucleus and stimulation of DNA repair.<sup>28</sup> Melatonin may activate NQO2, thereby reducing oxidative stress,<sup>190,191</sup> however, this mechanism's presence in these melanocytes is not fully understood.<sup>7</sup> Melatonin at concentrations higher than 1 nM within the cell can interact with the calcium/calmodulin complex leading to inhibition of NOS1-mediated generation of RNS, with potential reductions in RNS levels.<sup>63</sup> Melatonin may also inhibit the Keap1-E3 ligase complex and the ubiquitination and proteasomal degradation of Nrf2, thereby preserving high Nrf2 levels that translocate to the nucleus. In the nucleus, Nrf2 may couple with Maf, a transcription factor, allowing Nrf2 to bind ARE on the promoter region of genes encoding antioxidant enzymes (e.g., SOD and GPx), resulting in their increased expression and activity, which then convert ROS and RNS to unreactive products.<sup>1</sup> Direct effects are shown by solid lines and multiple reactions and signaling are shown by dashed lines. CAT, catalase; GPx, glutathione peroxidase; GR, glutathione reductase; RNS, reactive nitrogen species; ROS, reactive oxygen species; SOD, superoxide dismutase

eventually determining whether or not graying is reversible.<sup>68,76,134,135</sup>

A study using murine HFs demonstrated the protective effect that superoxide dismutase (SOD),<sup>202</sup> an enzyme involved in melatonin's antioxidant defense properties,<sup>89,189</sup> has against hair graying. Also, aged, gray HFs have increased reactivity to reducing and oxidizing agents when exposed to radiation-induced oxidative stress,<sup>203</sup> decreased antioxidant defense (e.g., decreased

CAT activity and expression),<sup>204</sup> and increased accumulation of tryptophan.<sup>205</sup> This invites two melatonin-related hypotheses: (a) decreased enzymatic conversion of tryptophan to melatonin in graying HFs, and/or (b) increased production of tryptophan used to enhance melatonin synthesis for combating oxidative stress within the HFPU.

The fine regulation of redox balance between free radicals and antioxidants is critical for maintaining

normal functions in human epidermal<sup>193,195</sup> and HF<sup>194</sup> melanocytes. Without the melatonin-associated antioxidant defenses, it is possible that human epidermal and HF melanocytes may be substantially more susceptible to oxidative damage that results in cellular dysfunction, such as directly impaired tyrosinase activity by blunting methionine sulfoxide repair<sup>135</sup> and apoptosis.<sup>49,134,204</sup> However, the potential association between reduced melatonin levels/expression in aging and graying HFs and other hypopigmentary conditions still needs to be clarified.

### 5.3 | Melatonin enhances the protection of melanocytes against UV radiation (UVR)

Oxidative stress generated by UVR and visible light (VL) has the potential to induce cosmetically unappealing hyperpigmentation.<sup>206</sup> For this reason, the use of topical and oral antioxidants has become increasingly prevalent as therapy in adjunct to sun protection to prevent UVR- and VL-induced hyperpigmentation.<sup>206,207</sup> Pronounced photoprotective effects of “natural” and synthetic antioxidants were demonstrated in animal and human studies when applied topically before exposure to UVR, but no protective effects by antioxidants (e.g., melatonin, vitamins) were found by some authors when applied after exposure to UVR.<sup>207</sup> In contrast, others have demonstrated the protective action of melatonin and metabolites applied directly after UVB exposure,<sup>28</sup> such as their protection from and reversal of UVB-induced damage in cultured human epidermal melanocytes.<sup>28</sup> Similar effects were seen for vitamin D derivatives.<sup>208–210</sup> It must be noted, however, that active forms of vitamin D are more efficient in photoprotection than melatonin.<sup>210,211</sup>

### 5.4 | Melatonin regulates senescence progression and promotes mitochondrial homeostasis

Mitochondria play a vital role in skin and there exists increasing evidence that mitochondrial dysfunction and oxidative stress are key features in senescence and aging skin with direct links to skin and hair aging phenotypes (e.g., uneven pigmentation and hair graying).<sup>68,212,213</sup> Melatonin is found in especially high concentrations in mitochondria,<sup>214,215</sup> where it is transported to,<sup>216</sup> synthesized,<sup>217</sup> or metabolized.<sup>92</sup> Within mitochondria, cytochrome c converts melatonin to its potent antioxidant metabolite, AFMK,<sup>91</sup> and its secondary product, AMK in the presence of H<sub>2</sub>O<sub>2</sub>.<sup>92</sup>

The abundance of damaging free radicals generated by oxidative phosphorylation makes the mitochondria an optimal location for such high concentrations of melatonin.<sup>11</sup> Various mechanisms have been proposed regarding melatonin's ability to reduce mitochondrial oxidative stress and help maintain mitochondrial homeostasis, however, these remain to be fully studied in the context of human melanocytes

One proposed antiaging mechanism that may be relevant in this context involves the stimulation of sirtuin3 (SIRT3) by melatonin in mitochondria, leading to the deacetylation and activation of SOD2, which enzymatically dismutates superoxide anion radicals.<sup>218</sup> Furthermore, melatonin can inhibit premature senescence by upregulating expression of sirtuin1 (SIRT1), which reduces oxidative stress, decreases expression and activation of p53, and inhibits nuclear factor kappa B (NF- $\kappa$ B) signaling.<sup>10</sup>

Melatonin may also act on mitochondrial uncoupling proteins to dissipate the proton gradient across the inner membrane to moderately reduce inner membrane potential, thereby increasing activities of complexes I and III, accelerating electron transport chain (ETC), electron transport, and decreasing electron leakage from the ETC; effects that reduce free radical formation.<sup>93</sup> Melatonin's alleviation of oxidative damage in the mitochondrial matrix and intermembrane space<sup>2</sup> has been proposed to decrease cardiolipin oxidation, mitochondrial permeability transition pore (MPTP) opening,<sup>219</sup> cytochrome c release, and mitochondria-related apoptosis, all of which are beneficial effects to slow aging and preserve cellular functioning,<sup>11</sup> likely also in human epidermal and HF melanocytes. Melatonin can also increase H<sub>2</sub>O<sub>2</sub> scavenging<sup>11</sup> and its metabolite 6-OHM can directly increase the electron flux through the respiratory chain and enhance ATP production by donating electrons.<sup>220</sup>

Finally, melatonin maintains the optimal mitochondrial membrane potential ( $\Delta\psi$ m)<sup>221</sup> through its abilities to block the MPTP in conditions of stress and activate uncoupling proteins in normal conditions.<sup>93</sup>

### 5.5 | Melatonin regulates melanocyte autophagic flux

Autophagy is a critical cellular process that, in part, involves the removal of misfolded or aggregated proteins and clearance of damaged organelles, such as mitochondria (mitophagy), endoplasmic reticulum, and peroxisomes.<sup>222</sup> Autophagy is activated in conditions of oxidative stress,<sup>223</sup> including aging<sup>224</sup> and plays a key role in protecting normal human epidermal melanocytes from oxidative stress-induced apoptosis, loss of

mitochondrial membrane potential, and intracellular ROS generation,<sup>225,226</sup> as well as in the regulation of melanogenesis, melanosome formation and maturation, and melanosome degradation in normal melanocytes and keratinocytes.<sup>227–230</sup>

The key role of melatonin in the regulation of autophagy has been documented in the context of various organ systems and pathologies.<sup>231</sup> Melatonin can help maintain cellular homeostasis either through autophagy promotion or suppression, depending on cellular requirements and oxidative stress levels.<sup>232</sup> Since autophagic flux is required for maintenance of anagen and thus pigment production in human HFs,<sup>233</sup> it is possible that the intrafollicular synthesis of melatonin<sup>30</sup> contributes to adequate autophagy levels. However, it is unknown whether melatonin impacts on autophagy in human epidermal and HF melanocytes. Yet, since melatonin and autophagy are so closely related to oxidative stress in melanocytes, a relationship between them is anticipated.<sup>224</sup>

Melatonin prevents the initiation of mitophagy through maintenance of the optimal  $\Delta\psi_m$ .<sup>234</sup> Also, melatonin may reduce autophagy in epidermal and HF melanocytes indirectly by either reversing mitochondrial dysfunction through reduced oxidative stress or by improving endoplasmic reticulum efficiency, resulting in less misfolded proteins, which are effects exerted by melatonin in the context of other organs systems and pathologies.<sup>231</sup>

SIRT1 is an autophagy substrate and stimulator that works by preventing the acetylation of key autophagy proteins (via deacetylation) (e.g., ATG5, ATG7, and ATG8/LC3).<sup>235,236</sup> SIRT1 levels are reduced through autophagic-lysosomal degradation in aging tissues, which could contribute to melanocyte cell cycle arrest and a pro-inflammatory senescence-associated secretory phenotype during skin aging.<sup>237</sup> Considering melatonin's ability to upregulate SIRT1 expression<sup>10</sup> (see Section 5.4), intracutaneously produced melatonin may thus positively regulate autophagy and exert antiaging properties by stabilizing SIRT1 levels. The role of melatonin in skin aging has been recently extensively reviewed.<sup>238</sup>

## 6 | MELATONIN AND PERIPHERAL CIRCADIAN CLOCK GENES

The peripheral clock genes *Bmal1* and *Per1* are known to control pigmentation in human epidermal and HF melanocytes while their silencing in human HFs ex vivo stimulates melanogenesis, tyrosinase expression and


activity, TYRP1/2 expression, melanocyte dendricity.<sup>186</sup> It is unknown how melatonin, the key neuroendocrine regulator of the central circadian clock,<sup>6</sup> impacts the pigmentary activity of human epidermal and HF melanocytes through the peripheral clock. Yet, cell culture studies (e.g., human epidermal keratinocytes<sup>239</sup> and mouse neuro2A cells<sup>95</sup>) provide instructive clues as follows: melatonin may regulate peripheral clock-associated pigmentary effects, probably through activation of Nrf2, which triggers PI3K/AKT signaling.<sup>28</sup> PI3K/AKT signaling leads to stimulation of both BMAL1<sup>95</sup> and then PER1, which inhibits melanogenesis enzymes (tyrosinase, TRP-1, and TRP-2) and melanogenesis,<sup>94,186</sup> as hypothesized in Figure 4 (for detailed discussion, see Supporting Information Text 1).

## 7 | OPEN KEY QUESTIONS AND MODELS TO ANSWER THEM

To decisively advance the field, several open questions in addition to those already posed above must be clarified.

### 7.1 | Does exogenous melatonin robustly inhibit melanogenesis in the human epidermis and/or HFs, and if so, by which mechanism(s)?

The majority of melatonin effects on mammalian melanogenesis have been observed in cell culture studies, even though—for the reasons discussed above—it is most meaningful to study melanocyte activities within their natural tissue habitat, rather than in isolation. Therefore, to best determine melatonin's therapeutic potential in pigmentary disorders, and to clarify definitively whether it indeed robustly inhibits human melanogenesis in situ, it is critical to study melatonin in human epidermal and HF melanocytes in skin and HF organ culture. In these ex vivo assays, besides pharmacological antagonist and blocking-antibody studies, gene silencing can be performed for mechanistic research to elucidate the exact mechanisms by which melatonin alters key regulatory elements of melanogenesis along the lines synthesized in Figures 1–4. It is important to do this in a strictly hair cycle-standardized manner as HF pigmentation is active only during active hair growth (anagen) and HF cycling impacts substantially on extrafollicular skin physiology (e.g., by a maximal HF production of melanotropic neuropeptides and growth factors during anagen), which may in turn also affect the response of intraepidermal melanocytes to melatonin.



**FIGURE 4** Schematic summary describing hypothesized mechanisms by which melatonin may regulate melanogenesis in normal human epidermal and HF melanocytes. Melatonin may activate the PI3K/AKT pathway, via Nrf2 activation,<sup>28</sup> to stimulate expression of *Bmal1*, thereby increasing BMAL1 levels.<sup>95</sup> BMAL1 may increase expression of Nrf2 to further stimulate this PI3K/AKT pathway<sup>240</sup> and PER1 to inhibit MITF downstream.<sup>186</sup> PER1 also translocates to the nucleus and inhibits transcriptional activity of BMAL1,<sup>241,242</sup> thereby preventing BMAL1's stimulation of MITF transcription.<sup>243</sup> Decreased MITF levels lead to decreased expression of melanogenesis enzymes tyrosinase, TRP-1, and TRP-2 and results in decreased melanogenesis.<sup>94</sup>

## 7.2 | Does melatonin regulate human melanocyte proliferation, survival, and/or senescence under physiological circumstances and via which receptor or pathway?

Similarly, whether melatonin regulates the proliferation, survival and/or senescence of human epidermal and HF melanocytes *under physiological conditions* remains unclear. There is sufficient evidence that melatonin can affect these phenotypic traits in vitro. However, it remains to be established where melatonin ranks in the hierarchy of other local regulators of these melanocyte activities. Again, this is best studied in human skin and HF organ culture assays ex vivo. Ideally, this is complemented by studying human skin xenotransplants on SCID mice for long-term preclinical in vivo studies directly in the human target organ, and by knocking out or overexpressing cell type-dependent local production of melatonin, individual receptors (MT1 vs MT2), or different signaling pathways in defined human skin cell populations that are cocultured under 3D conditions in human skin “equivalents.” This will also require the development of MT1-selective agents to match the abundance of available MT2-selective agents.<sup>244</sup>

## 7.3 | Can melatonin prevent and/or treat pigmentation disorders?

Ultimately, we need definitive answers to this question regarding which human pigmentation disorders can effectively be prevented or managed by melatonin administration, either topically or systemically. Above, we have delineated the rationale and preliminary clinical observations that encourage one to explore melatonin treatment in the pathophysiology and/or management of, for example, vitiligo, melasma, hair graying, and solar-related hyperpigmentation. However, more rigorous, well-controlled, prospective, randomized clinical trials

are needed to determine utility and mode of application (systemic or topical) of melatonin, its metabolites, and its chemically synthesized derivatives, using optimally standardized and sensitive methods for recording changes in human skin/hair pigmentation. Also, skin or HF tissue samples from patients with such pigmentary disorders (perhaps beginning with vitiligo, melasma, and hair graying) should be systematically screened for abnormalities in the cutaneous melatonin system, then organ-cultured, exposed to melatonin of varying concentrations, and analyzed for changes in key melanocyte biology read-outs in situ (e.g., melanin production, tyrosinase activity, expression of c-kit, gp100, MITF, TRP-1, TRP-2, Ki-67, senescence markers).

## 8 | THERAPEUTIC PERSPECTIVES

The multiple levels at which melatonin and its metabolites could intervene with human skin pigmentation invite therapeutic applications. In addition, melatonin's safety, lack of or very low toxicity, and pleiotropic effects (e.g., UV protection, potent antioxidant activity, DNA repair, anti-aging, anti-inflammation, and melanogenesis inhibition) make melatonin an attractive therapeutic candidate for treatment of pigmentary disorders, such as melasma<sup>175</sup> and acanthosis nigrans-associated hyperpigmentation.<sup>174</sup>

Its photoprotective,<sup>59,60</sup> antiphotoreactive,<sup>10,50,177,245–247</sup> antioxidative damage-protective,<sup>5,28,86,89,92,189,190</sup> and DNA damage-repair<sup>28</sup> properties also raise the possibility that melatonin may be useful to slow intrinsic and extrinsic skin aging and may exert melanocyte-protective properties in vitiligo and perhaps even aging-associated hair graying resulting from oxidative damage to the HFPU.<sup>68</sup> In fact, melatonin and its metabolites (e.g., AFMK) protect melanocytes in vitro<sup>28</sup> from UV-induced DNA damage and apoptosis<sup>50,248</sup> when applied both before<sup>249</sup> and immediately after UVB exposure.<sup>28</sup> This



renders melatonin an effective therapeutic candidate for the prevention and management of solar radiation-induced pigmentation disorders.<sup>21,59,250,251</sup> Finally, melatonin's regulation of autophagy<sup>252</sup> (see section 5.5) might be exploited to treat pigmentary disorders with recognized autophagic defects such as vitiligo,<sup>223,253</sup> tuberous sclerosis,<sup>254</sup> and Cockayne syndrome.<sup>255</sup>

Due to its ability to penetrate the stratum corneum<sup>256</sup> and to thus evade prominent first-pass metabolism of oral melatonin by the liver,<sup>56</sup> topical administration of melatonin may be superior to the oral route, and permits administration of high melatonin doses directly to human skin target cells, namely epidermal and HF melanocytes and their keratinocyte environment in the EPU and HFPU. Indeed, the use of topical sunscreen fortified with melatonin offers superior sun protection and the ability to counteract UVR-induced oxidative stress.<sup>248</sup> A topical sunscreen formulation fortified with melatonin and pumpkin seed oil reportedly had enhanced photoprotective effects.<sup>257</sup> Also, the application of 12.5% melatonin cream protects skin from natural sunlight-induced erythema.<sup>253</sup> New topical formulations such as nanostructured lipid carriers<sup>158,258</sup> and ethosomes<sup>259</sup> promise optimized melatonin delivery in future clinical trials.

Given that theophylline (which is licensed for topical application as a cosmetic agent) can increase melatonin levels released by organ-cultured human skin into the medium<sup>260</sup> while noradrenaline stimulates melatonin synthesis within human scalp HFs *ex vivo*,<sup>30</sup> it is also possible that the intracutaneous synthesis of melatonin can be stimulated by topically applied agents that increase intracellular cAMP levels and thus intracutaneous production of endogenous melatonin.

To our knowledge, genetic disorders associated with melatonin deficiency and its receptor deficiencies have not yet been described but may well have been missed. In addition, melatonin's nuclear receptors, as opposed to its membrane receptors (MT1 and MT2), still must be definitively identified. Of note, many of melatonin's protective effects in melanocytes described above, such as melatonin's role as a free radical scavenger<sup>89,90</sup> and stimulator of DNA repair<sup>28</sup> and antioxidant enzyme expression and activity<sup>1</sup> are independent of MT1 and MT2 signaling. Therefore, MT1 and/or MT2 genetic disorders would not directly alter receptor-independent protective effects in melanocytes. While deficiencies in melatonin synthesis or receptor expression levels in the human system, namely in human skin, clearly await more systematic scrutiny, this limits what can be deduced from the study of dysfunctional MT1/2, even if patients become identified, for example, with receptor mutations. Furthermore, no genetically mutant mice are currently

known that have substantial melatonin synthesis or MT receptor deficiencies in their skin.

## 9 | CONCLUSIONS

1. In normal human epidermal melanocytes, melatonin and its metabolites, such as AFMK, 6-OHM, and 5-MT, inhibit melanogenesis, tyrosinase activity, and melanocyte proliferation *in vitro*. Yet, it is unclear how robustly this translates to the physiological tissue context in human epidermis and HFs. Instructive organ culture assays are readily available to clarify this.
2. Melatonin may inhibit melanogenesis not only by stimulation of MT receptors (MT1/2), but also indirectly by cell desensitization to estrogens, reducing skin sensitivity to  $\alpha$ -MSH stimulation, and activation of Nrf2 and PI3k/AKT pathways and/or MAPK signaling. Additional indirect mechanisms/targets by which melatonin may regulate human melanocyte physiology include calcium-calmodulin complex, NOS1, p53, cytochrome c, ETC enzymes, SIRT3/SOD2, and possibly NQO2 (see Figures 1 and 2).
3. Besides accounting for dose-, application mode-, species-, gender-, age-, and ethnicity-dependent differences in the melatonin response of melanocytes in a given tissue location, much greater attention must be paid to the tissue context in which melatonin affects human melanocyte physiology, such as the specific hormonal tissue environment, internal and external stressors, and local determinants of melatonin metabolism through indolic and kynuric pathways.
4. There is good *in vitro* evidence that melatonin can unfold powerful oxidative damage-limiting effects on melanocytes, namely under skin photodamage conditions, through MT1/2 activation, direct ROS scavenging, Nrf2 activation, promotion of mitochondrial homeostasis, calcium/calmodulin complex-induced inhibition of NOS1, and possible action on NQO2. Yet, whether melatonin really does so under physiological conditions and inhibits melanocyte senescence in human epidermis and HFs *in situ*, remains to be conclusively demonstrated.
5. Dysfunctional mitochondria and inadequate autophagy may also contribute to premature senescence and accelerated aging in human epidermal and HF melanocytes. Melatonin's high concentrations in mitochondria and ability to help maintain mitochondrial homeostasis and modulate mitophagy justify the expectation that melatonin will become useful not only in limiting melanocyte senescence, a potential driver overall skin aging, but also invites clinical melatonin

applications in the emerging field of “mitochondrial dermatology.”<sup>261</sup>

6. Since silencing of the core peripheral clock genes, *Clock*, *Bmal1*, and *Per1* stimulates melanogenesis in human epidermis and HFs in situ, melatonin may regulate peripheral clock-controlled pigmentary effects. One conceivable pathway is the activation of Nrf2 and PI3K/AKT signaling, which is expected to promote BMAL1 and PER1's downstream melanogenesis-inhibitory effects, for example, on tyrosinase activity.
7. The field is challenged to now move from in vitro to ex vivo and preclinical in vivo studies, using available human skin and HF organ culture assays as well as human skin xenotransplants on immunocompromised mice, to definitively clarify the relevance of melatonin in human melanocyte physiology and to more rigorously probe how therapeutically useful melatonin really is in selected human pigmentary disorders, ranging from hair graying to melasma and vitiligo.

## ACKNOWLEDGEMENT

R. P. was supported by a Frost Endowed Scholarship. Additional support for review writing was provided by NIH grants 1R01AR073004-01A1, R01AR071189-01A1, and VA merit grant (no. 1I01BX004293-01A1) to A. T. S. The paper is dedicated to A. B. L., a discoverer of melatonin, and mentor of one of the co-authors (A. T. S.).

## DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

## ORCID

Alec Sevilla  <https://orcid.org/0000-0001-7111-8557>

Jérémy Chéret  <https://orcid.org/0000-0002-4811-8580>

Radomir M. Slominski  <https://orcid.org/0000-0002-2929-1118>

Andrzej T. Slominski  <http://orcid.org/0000-0001-8963-3995>

Ralf Paus  <https://orcid.org/0000-0002-3492-9358>

## REFERENCES

1. Manchester LC, Coto-Montes A, Boga JA, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. *J Pineal Res.* 2015;59(4):403-419. doi:10.1111/jpi.12267
2. Reiter RJ, Rosales-Corral S, Tan DX, Jou MJ, Galano A, Xu B. Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas. *Cell Mol Life Sci.* 2017;74(21):3863-3881. doi:10.1007/s00018-017-2609-7
3. Dubocovich ML. Melatonin receptors: role on sleep and circadian rhythm regulation. *Sleep Med.* 2007;8:34-42. doi:10.1016/j.sleep.2007.10.007
4. Reiter RJ, Tan DX, Rosales-Corral S, Manchester LC. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. *Mini Rev Med Chem.* 2013;13(3):373-384. doi:10.2174/1389557511313030006
5. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? *J Pineal Res.* 2007;42(1):28-42. doi:10.1111/j.1600-079X.2006.00407.x
6. Pandi-Perumal SR, Srinivasan V, Maestroni GJM, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: nature's most versatile biological signal? *FEBS J.* 2006;273(13):2813-2838. doi:10.1111/j.1742-4658.2006.05322.x
7. Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. *Cell Mol Life Sci.* 2014;71(16):2997-3025. doi:10.1007/s00018-014-1579-2
8. Slominski A, Tobin DJ, Zmijewski MA, Wortsman J, Paus R. Melatonin in the skin: synthesis, metabolism and functions. *Trends Endocrinol. Metab.* 2008;19(1):17-24. doi:10.1016/j.tem.2007.10.007
9. Reiter RJ, Sharma R, Rosales-Corral S. Anti-warburg effect of melatonin: a proposed mechanism to explain its inhibition of multiple diseases. *Int J Mol Sci.* 2021;22(2):E764. doi:10.3390/ijms22020764
10. Ma L, Liu Q, Tian M, Tian X, Gao L. Mechanisms of melatonin in anti-aging and its regulation effects in radiation-induced premature senescence. *Rad Med Protect.* 2021;2(1):33-37. doi:10.1016/j.radmp.2021.01.003
11. Reiter RJ, Tan DX, Rosales-Corral S, Galano A, Zhou XJ, Xu B. Mitochondria: central organelles for melatonin's antioxidant and anti-aging actions. *Molecules.* 2018;23(2):509. doi:10.3390/molecules23020509
12. Majidinia M, Reiter RJ, Shakouri SK, Yousefi B. The role of melatonin, a multitasking molecule, in retarding the processes of ageing. *Ageing Res Rev.* 2018;47:198-213. doi:10.1016/j.arr.2018.07.010
13. Ashrafzadeh M, Najafi M, Kavyiani N, Mohammadinejad R, Farkhondeh T, Samarghandian S. Anti-inflammatory activity of melatonin: a focus on the role of NLRP3 inflammasome. *Inflammation.* 2021;44(4):1207-1222. doi:10.1007/s10753-021-01428-9
14. Sheikholeslami S, Aryafar T, Abedi-Firouzjah R, et al. The role of melatonin on radiation-induced pneumonitis and lung fibrosis: a systematic review. *Life Sci.* 2021;281:119721. doi:10.1016/j.lfs.2021.119721
15. Pham L, Baiocchi L, Kennedy L, et al. The interplay between mast cells, pineal gland, and circadian rhythm: links between histamine, melatonin, and inflammatory mediators. *J Pineal Res.* 2021;70(2):e12699. doi:10.1111/jpi.12699
16. Fischer TW, Zmijewski MA, Zbytek B, et al. Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines. *Int J Oncol.* 2006;29(3):665-672. doi:10.3892/ijo.29.3.665
17. Slominski A, Pruski D. Melatonin inhibits proliferation and melanogenesis in rodent melanoma cells. *Exp Cell Res.* 1993;206(2):189-194. doi:10.1006/excr.1993.1137
18. Moreno ACR, Saito RF, Tiago M, et al. Melatonin inhibits human melanoma cells proliferation and invasion via cell

- cycle arrest and cytoskeleton remodeling. *Melatonin Res.* 2020;3(2):194-209. doi:10.32794/mr11250057
19. Alvarez-Artme A, Cernuda-Cernuda R, Cepas V, et al. Melatonin-induced cytoskeleton reorganization leads to inhibition of melanoma cancer cell proliferation. *Int J Mol Sci.* 2020;21(2):548. doi:10.3390/ijms21020548
  20. Samanta S. Melatonin: an endogenous miraculous indolamine, fights against cancer progression. *J Cancer Res Clin Oncol.* 2020;146(8):1893-1922. doi:10.1007/s00432-020-03292-w
  21. Janjetovic Z, Nahmias ZP, Hanna S, et al. Melatonin and its metabolites ameliorate ultraviolet B-induced damage in human epidermal keratinocytes. *J Pineal Res.* 2014;57(1):90-102. doi:10.1111/jpi.12146
  22. Kleszczynski K, Bilska B, Stegemann A, et al. Melatonin and its metabolites ameliorate uvr-induced mitochondrial oxidative stress in human MNT-1 melanoma cells. *Int J Mol Sci.* 2018;19(12):3786. doi:10.3390/ijms19123786
  23. Baltatu OC, Senar S, Campos LA, Cipolla-Neto J. Cardio-protective melatonin: translating from proof-of-concept studies to therapeutic use. *IJMS.* 2019;20(18):4342. doi:10.3390/ijms20184342
  24. Xu Z, You W, Liu J, Wang Y, Shan T. Elucidating the regulatory role of melatonin in brown, white, and beige adipocytes. *Adv Nutr.* 2019;11:447-460. doi:10.1093/advances/nmz070
  25. Munmun F, Witt-Enderby PA. Melatonin effects on bone: Implications for use as a therapy for managing bone loss. *J Pineal Res.* 2021;71(1):e12749. doi:10.1111/jpi.12749
  26. Pal PK, Sarkar S, Chattopadhyay A, Tan DX, Bandyopadhyay D. Enterochromaffin cells as the source of melatonin: key findings and functional relevance in mammals. *Melatonin Res.* 2019;2(4):61-82. doi:10.32794/mr11250041
  27. Segovia-Roldan M, Diez ER, Pueyo E. Melatonin to rescue the aged heart: antiarrhythmic and antioxidant benefits. *Oxid Med Cell Longevity.* 2021;2021:e8876792. doi:10.1155/2021/8876792
  28. Janjetovic Z, Jarrett SG, Lee EF, Duprey C, Reiter RJ, Slominski AT. Melatonin and its metabolites protect human melanocytes against UVB-induced damage: involvement of NRF2-mediated pathways. *Sci Rep.* 2017;7(1):1274. doi:10.1038/s41598-017-01305-2
  29. Mehraein F, Talebi R, Jameie B, Joghataie MT, Madjd Z. Neuroprotective effect of exogenous melatonin on dopaminergic neurons of the substantia nigra in ovariectomized rats. *Iran Biomed J.* 2011;15(1-2):44-50.
  30. Kobayashi H, Kromminga A, Dunlop TW, et al. A role of melatonin in neuroectodermal-mesodermal interactions: the hair follicle synthesizes melatonin and expresses functional melatonin receptors. *FASEB J.* 2005;19(12):1710-1712. doi:10.1096/fj.04-2293fje
  31. Ma N, Zhang J, Reiter RJ, Ma X. Melatonin mediates mucosal immune cells, microbial metabolism, and rhythm crosstalk: a therapeutic target to reduce intestinal inflammation. *Med Res Rev.* 2020;40(2):606-632. doi:10.1002/med.21628
  32. Moradkhani F, Moloudizargari M, Fallah M, Asghari N, Khoei HH, Asghari MH. Immunoregulatory role of melatonin in cancer. *J Cell Physiol.* 2020;235(2):745-757. doi:10.1002/jcp.29036
  33. Chen T, Luo Y, Li Q, et al. Melatonin reduces radiation damage in inner ear. *J Radiat Res.* 2021;62(2):217-225. doi:10.1093/jrr/rraa137
  34. Li Y, Wu H, Liu N, et al. Melatonin exerts an inhibitory effect on insulin gene transcription via MTNR1B and the downstream Raf-1/ERK signaling pathway. *Int J Mol Med.* 2017;41:955-961. doi:10.3892/ijmm.2017.3305
  35. Sato K, Meng F, Francis H, et al. Melatonin and circadian rhythms in liver diseases: functional roles and potential therapies. *J Pineal Res.* 2020;68(3):12639. doi:10.1111/jpi.12639
  36. Niu YJ, Zhou W, Nie ZW, Shin KT, Cui XS. Melatonin enhances mitochondrial biogenesis and protects against rotenone-induced mitochondrial deficiency in early porcine embryos. *J Pineal Res.* 2020;68(2):e12627. doi:10.1111/jpi.12627
  37. Dudka Y, Zamorskii I, Shchudrova T, Petriuk A, Kopchuk T, Drachuk V. Nephroprotective mechanisms, therapeutic potential and perspective on melatonin use for drug-induced nephropathy. *Med Sci.* 2021;25(107):163-169.
  38. Alghamdi BS. The neuroprotective role of melatonin in neurological disorders. *J Neurosci Res.* 2018;96(7):1136-1149. doi:10.1002/jnr.24220
  39. Huang R, Xu Y, Lu X, et al. Melatonin protects inner retinal neurons of newborn mice after hypoxia-ischemia. *J Pineal Res.* 2021;71:71. doi:10.1111/jpi.12716
  40. Diéguez HH, González Fleitas MF, Aranda ML, et al. Melatonin protects the retina from experimental nonexudative age-related macular degeneration in mice. *J Pineal Res.* 2020;68(4):e12643. doi:10.1111/jpi.12643
  41. Cipolla-Neto J, Amaral FG, Soares JM Jr., et al. The crosstalk between melatonin and sex steroid hormones. *Neuroendocrinology.* 2021;112:115-129. doi:10.1159/000516148
  42. Roy D, Belsham DD. Melatonin receptor activation regulates GnRH gene expression and secretion in GT1-7 GnRH neurons. *J Biol Chem.* 2002;277(1):251-258. doi:10.1074/jbc.M108890200
  43. González A, Alonso-González C, González-González A, Menéndez-Menéndez J, Cos S, Martínez-Campa C. Melatonin as an adjuvant to antiangiogenic cancer treatments. *Cancers.* 2021;13(13):3263. doi:10.3390/cancers13133263
  44. Kleszczynski K, Böhm M. Can melatonin and its metabolites boost the efficacy of targeted therapy in patients with advanced melanoma? *Exp Dermatol.* 2020;29(9):860-863. doi:10.1111/exd.14144
  45. Pariente R, Bejarano I, Rodríguez AB, Pariente JA, Espino J. Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. *Mol Cell Biochem.* 2018;440(1-2):43-51. doi:10.1007/s11010-017-3154-2
  46. Reiter RJ, Rosales-Corral SA, Tan DX, et al. Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis. *Int J Mol Sci.* 2017;18(4):843. doi:10.3390/ijms18040843
  47. Zhang J, Xie T, Zhong X, et al. Melatonin reverses nasopharyngeal carcinoma cisplatin chemoresistance by

- inhibiting the Wnt/ $\beta$ -catenin signaling pathway. *Aging*. 2020; 12(6):5423-5438. doi:10.18632/aging.102968
48. Slominski A, Fischer TW, Zmijewski MA, et al. On the role of melatonin in skin physiology and pathology. *Endocrine*. 2005; 27(2):137-148. doi:10.1385/ENDO:27:2:137
  49. Fischer TW, Sweatman TW, Semak I, Sayre RM, Wortsman J, Slominski A. Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems. *FASEB J*. 2006;20(9):1564-1566. doi:10.1096/fj.05-5227fje
  50. Skobowiat C, Brożyna AA, Janjetovic Z, et al. Melatonin and its derivatives counteract the ultraviolet B radiation-induced damage in human and porcine skin ex vivo. *J Pineal Res*. 2018;65(2):e12501. doi:10.1111/jpi.12501
  51. Dong K, Goyarts E, Rella A, Pelle E, Wong YH, Pernodet N. Age associated decrease of MT-1 melatonin receptor in human dermal skin fibroblasts impairs protection against UV-induced DNA damage. *Int J Mol Sci*. 2020;21(1):E326. doi:10.3390/ijms21010326
  52. Koçtürk S, Yüksel Egrilmez M, Aktan Ş, et al. Melatonin attenuates the detrimental effects of UVA irradiation in human dermal fibroblasts by suppressing oxidative damage and MAPK/AP-1 signal pathway in vitro. *Photodermatol Photoimmunol Photomed*. 2019;35(4):221-231. doi:10.1111/phpp.12456
  53. Kaczmarek-Szczepańska B, Ostrowska J, Kozłowska J, et al. Evaluation of polymeric matrix loaded with melatonin for wound dressing. *Int J Mol Sci*. 2021;22(11):5658. doi:10.3390/ijms22115658
  54. Lerner AB, Case JD, Takahashi Y. Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands. *J Biol Chem*. 1960;235:1992-1997.
  55. Karasek M. Melatonin, human aging, and age-related diseases. *Exp Gerontol*. 2004;39(11-12):1723-1729. doi:10.1016/j.exger.2004.04.012
  56. Milani M, Sparavigna A. Antiaging efficacy of melatonin-based day and night creams: a randomized, split-face, assessor-blinded proof-of-concept trial. *CCID*. 2018;11:51-57. doi:10.2147/CCID.S153905
  57. Poeggeler B, Reiter RJ, Tan DX, Chen LD, Manchester LC. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. *J Pineal Res*. 1993;14(4):151-168. doi:10.1111/j.1600-079x.1993.tb00498.x
  58. Fischer TW, Slominski A, Zmijewski MA, Reiter RJ, Paus R. Melatonin as a major skin protectant: from free radical scavenging to DNA damage repair. *Exp Dermatol*. 2008;17(9):713-730. doi:10.1111/j.1600-0625.2008.00767.x
  59. Slominski AT, Kleszczyński K, Semak I, et al. Local melatoninergic system as the protector of skin integrity. *Int J Mol Sci*. 2014;15(10):17705-17732. doi:10.3390/ijms151017705
  60. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. *FASEB J*. 2005;19(2):176-194. doi:10.1096/fj.04-2079rev
  61. Pourhanifeh MH, Mahdavinia M, Reiter RJ, Asemi Z. Potential use of melatonin in skin cancer treatment: a review of current biological evidence. *J Cell Physiol*. 2019;234(8):12142-12148. doi:10.1002/jcp.28129
  62. Fischer TW, Slominski A, Tobin DJ, Paus R. Melatonin and the hair follicle. *J Pineal Res*. 2007;44(1):1-15. doi:10.1111/j.1600-079X.2007.00512.x
  63. Slominski AT, Hardeland R, Zmijewski MA, Slominski RM, Reiter RJ, Paus R. Melatonin: a cutaneous perspective on its production, metabolism, and functions. *J Invest Dermatol*. 2018;138(3):490-499. doi:10.1016/j.jid.2017.10.025
  64. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. *Physiol Rev*. 2004;84(4):1155-1228. doi:10.1152/physrev.00044.2003
  65. Slominski AT, Hardeland R, Reiter RJ. When the circadian clock meets the melanin pigmentary system. *J Invest Dermatol*. 2015;135(4):943-945. doi:10.1038/jid.2014.553
  66. Moreiras H, Seabra MC, Barral DC. Melanin transfer in the epidermis: the pursuit of skin pigmentation control mechanisms. *Int J Mol Sci*. 2021;22(9):4466. doi:10.3390/ijms22094466
  67. Tadokoro R, Takahashi Y. Intercellular transfer of organelles during body pigmentation. *Curr Opin Genet Dev*. 2017;45:132-138. doi:10.1016/j.gde.2017.05.001
  68. O'Sullivan JDB, Nicu C, Picard M, et al. The biology of human hair greying. *Biological Reviews*. 2021;96(1):107-128. doi:10.1111/brv.12648
  69. Slominski A, Wortsman J, Plonka PM, Schallreuter KU, Paus R, Tobin DJ. Hair follicle pigmentation. *J Invest Dermatol*. 2005;124(1):13-21. doi:10.1111/j.0022-202X.2004.23528.x
  70. Tobin DJ. The cell biology of human hair follicle pigmentation. *Pigment Cell Melanoma Res*. 2011;24(1):75-88. doi:10.1111/j.1755-148X.2010.00803.x
  71. Carrillo-Vico A, Lardone P, Álvarez-Sánchez N, Rodríguez-Rodríguez A, Guerrero J. Melatonin: buffering the immune system. *IJMS*. 2013;14(4):8638-8683. doi:10.3390/ijms14048638
  72. Slominski A, Zbytek B, Pisarchik A, Slominski RM, Zmijewski MA, Wortsman J. CRH functions as a growth factor/cytokine in the skin. *J Cell Physiol*. 2006;206(3):780-791. doi:10.1002/jcp.20530
  73. Slominski AT, Zmijewski MA, Skobowiat C, Zbytek B, Slominski RM, Steketee JD. Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. *Adv Anat Embryol Cell Biol*. 2012;212:v-115. doi:10.1007/978-3-642-19683-6\_1
  74. Samuelov L, Sprecher E, Sugawara K, et al. Topobiology of human pigmentation: P-cadherin selectively stimulates hair follicle melanogenesis. *J Invest Dermatol*. 2013;133(6):1591-1600. doi:10.1038/jid.2013.18
  75. Sobiepanek A, Baran J, Milner-Krawczyk M, Kobiela T. Different types of surface modification used for improving the adhesion and interactions of skin cells. *Open Access J Biomed Sci*. 2020;2:275-278. doi:10.38125/OAJBS.000161
  76. Zhang B, Ma S, Rachmin I, et al. Hyperactivation of sympathetic nerves drives depletion of melanocyte stem cells. *Nature*. 2020;577(7792):676-681. doi:10.1038/s41586-020-1935-3
  77. Nicu C, O'Sullivan JDB, Ramos R, et al. Dermal adipose tissue secretes HGF to Promote human hair growth and pigmentation. *J Invest Dermatol*. 2021;141(7):1633-1645. doi:10.1016/j.jid.2020.12.019
  78. Lindner G, Menrad A, Gherardi E, et al. Involvement of hepatocyte growth factor/scatter factor and Met receptor



- signaling in hair follicle morphogenesis and cycling. *FASEB J*. 2000;14(2):319-332. doi:10.1096/fasebj.14.2.319
79. Slominski A, Paus R, Plonka P, et al. Melanogenesis during the anagen-catagen-telogen transformation of the murine hair cycle. *J Invest Dermatol*. 1994;102(6):862-869. doi:10.1111/1523-1747.ep12382606
  80. Semak I, Korik E, Naumova M, Wortsman J, Slominski A. Serotonin metabolism in rat skin: characterization by liquid chromatography-mass spectrometry. *Arch Biochem Biophys*. 2004;421(1):61-66. doi:10.1016/j.abb.2003.08.036
  81. Slominski A, Baker J, Rosano TG, et al. Metabolism of serotonin to N-acetylserotonin, melatonin, and 5-methoxytryptamine in hamster skin culture. *J Biol Chem*. 1996;271(21):12281-12286. doi:10.1074/jbc.271.21.12281
  82. Slominski A, Pisarchik A, Semak I, et al. Serotonergic and melatonergic systems are fully expressed in human skin. *FASEB J*. 2002;16(8):896-898. doi:10.1096/fj.01-0952fje
  83. Slominski AT, Kim TK, Kleszczyński K, et al. Characterization of serotonin and N-acetylserotonin systems in the human epidermis and skin cells. *J Pineal Res*. 2020;68(2):e12626. doi:10.1111/jpi.12626
  84. Slominski A, Semak I, Pisarchik A, Sweatman T, Szczesniowski A, Wortsman J. Conversion of L-tryptophan to serotonin and melatonin in human melanoma cells. *FEBS Lett*. 2002;511(1-3):102-106. doi:10.1016/S0014-5793(01)03319-1
  85. Slominski A, Pisarchik A, Johansson O, et al. Tryptophan hydroxylase expression in human skin cells. *Biochim Biophys Acta*. 2003;1639(2):80-86. doi:10.1016/S0925-4439(03)00124-8
  86. Slominski AT, Zmijewski MA, Semak I, et al. Melatonin, mitochondria, and the skin. *Cell Mol Life Sci*. 2017;74(21):3913-3925. doi:10.1007/s00018-017-2617-7
  87. Boutin JA. Quinone reductase 2 as a promising target of melatonin therapeutic actions. *Expert Opin Ther Targets*. 2016;20(3):303-317. doi:10.1517/14728222.2016.1091882
  88. Vella F, Ferry G, Delagrangé P, Boutin JA. NRH:quinone reductase 2: an enzyme of surprises and mysteries. *Biochem Pharmacol*. 2005;71(1-2):1-12. doi:10.1016/j.bcp.2005.09.019
  89. Jockers R, Delagrangé P, Dubocovich ML, et al. Update on melatonin receptors: IUPHAR Review 20. *Br J Pharmacol*. 2016;173(18):2702-2725. doi:10.1111/bph.13536
  90. Mayo JC, Sainz RM, González-Menéndez P, Hevia D, Cernuda-Cernuda R. Melatonin transport into mitochondria. *Cell Mol Life Sci*. 2017;74(21):3927-3940. doi:10.1007/s00018-017-2616-8
  91. Semak I, Naumova M, Korik E, Terekhov V, Wortsman J, Slominski A. A novel metabolic pathway of melatonin: oxidation by cytochrome C. *Biochemistry*. 2005;44(26):9300-9307. doi:10.1021/bi050202d
  92. Slominski AT, Semak I, Fischer TW, et al. Metabolism of melatonin in the skin: why is it important? *Exp Dermatol*. 2017;26(7):563-568. doi:10.1111/exd.13208
  93. Tan DX, Manchester LC, Qin L, Reiter RJ. Melatonin: a mitochondrial targeting molecule involving mitochondrial protection and dynamics. *Int J Mol Sci*. 2016;17(12). doi:10.3390/ijms17122124
  94. Shin JM, Kim MY, Sohn KC, et al. Nrf2 negatively regulates melanogenesis by modulating PI3K/Akt signaling. *PLOS One*. 2014;9(4):e96035. doi:10.1371/journal.pone.0096035
  95. Beker MC, Caglayan B, Caglayan AB, et al. Interaction of melatonin and Bmal1 in the regulation of PI3K/AKT pathway components and cellular survival. *Sci Rep*. 2019;9(1):19082. doi:10.1038/s41598-019-55663-0
  96. Mannino G, Pernici C, Serio G, Gentile C, Berteau CM. Melatonin and phytemelatonin: chemistry, biosynthesis, metabolism, distribution and bioactivity in plants and animals-an overview. *Int J Mol Sci*. 2021;22(18):9996. doi:10.3390/ijms22189996
  97. Hardeland R. Melatonin, its metabolites and their interference with reactive nitrogen compounds. *Molecules*. 2021;26(13):4105. doi:10.3390/molecules26134105
  98. Oishi A, Gbahou F, Jockers R. Melatonin receptors, brain functions, and therapies. *Handb Clin Neurol*. 2021;179:345-356. doi:10.1016/B978-0-12-819975-6.00022-4
  99. Fiore A, Murray PJ. Tryptophan and indole metabolism in immune regulation. *Curr Opin Immunol*. 2021;70:7-14. doi:10.1016/j.coi.2020.12.001
  100. Slominski A, Pisarchik A, Semak I, Sweatman T, Wortsman J. Characterization of the serotonergic system in the C57BL/6 mouse skin. *Eur J Biochem*. 2003;270(16):3335-3344. doi:10.1046/j.1432-1033.2003.03708.x
  101. Jou MJ, Peng TI, Yu PZ, et al. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. *J Pineal Res*. 2007;43(4):389-403. doi:10.1111/j.1600-079X.2007.00490.x
  102. Menendez-Pelaez A, Poeggeler B, Reiter RJ, Barlow-Walden L, Pablos MI, Tan DX. Nuclear localization of melatonin in different mammalian tissues: immunocytochemical and radioimmunoassay evidence. *J Cell Biochem*. 1993;53(4):373-382. doi:10.1002/jcb.240530415
  103. Rodríguez MI, Escames G, López LC, et al. Improved mitochondrial function and increased life span after chronic melatonin treatment in senescent prone mice. *Exp Gerontol*. 2008;43(8):749-756. doi:10.1016/j.exger.2008.04.003
  104. Yu H, Dickson EJ, Jung SR, Koh DS, Hille B. High membrane permeability for melatonin. *J Gen Physiol*. 2016;147(1):63-76. doi:10.1085/jgp.201511526
  105. Hacışevki A, Baba B. An overview of melatonin as an antioxidant molecule: a biochemical approach. In: Manuela Drăgoi C, Crenguța Nicolae A, eds. *Melatonin—Molecular Biology, Clinical and Pharmaceutical Approaches*. IntechOpen; 2018. doi:10.5772/intechopen.79421
  106. Tordjman S, Chokron S, Delorme R, et al. Melatonin: pharmacology, functions and therapeutic benefits. *Curr Neuropharmacol*. 2017;15(3):434-443. doi:10.2174/1570159X14666161228122115
  107. Slominski RM, Reiter RJ, Schlambitz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. *Mol Cell Endocrinol*. 2012;351(2):152-166. doi:10.1016/j.mce.2012.01.004
  108. Kallen J, Schlaeppli JM, Bitsch F, Delhon I, Fournier B. Crystal structure of the human ROR $\alpha$  Ligand binding domain in complex with cholesterol sulfate at 2.2 Å. *J Biol Chem*. 2004;279(14):14033-14038. doi:10.1074/jbc.M400302200
  109. Slominski AT, Zmijewski MA, Jetten AM. ROR $\alpha$  is not a receptor for melatonin. *BioEssays*. 2016;38(12):1193-1194. doi:10.1002/bies.201600204

110. Slominski AT, Kim TK, Takeda Y, et al. ROR $\alpha$  and ROR  $\gamma$  are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D. *FASEB J*. 2014;28(7):2775-2789. doi:10.1096/fj.13-242040
111. Ma H, Kang J, Fan W, He H, Huang F. ROR: Nuclear receptor for melatonin or not? *Molecules*. 2021;26(9):2693. doi:10.3390/molecules26092693
112. Slominski A, Paus R, Schadendorf D. Melanocytes as “sensory” and regulatory cells in the epidermis. *J Theor Biol*. 1993;164(1):103-120. doi:10.1006/jtbi.1993.1142
113. Slominski A, Paus R. Melanogenesis is coupled to murine anagen: toward new concepts for the role of melanocytes and the regulation of melanogenesis in hair growth. *J Invest Dermatol*. 1993;101(1 Suppl):90S-97S. doi:10.1111/1523-1747.ep12362991
114. Slominski AT, Zmijewski MA, Plonka PM, Szaflarski JP, Paus R. How UV light touches the brain and endocrine system through skin, and why. *Endocrinology*. 2018;159(5):1992-2007. doi:10.1210/en.2017-03230
115. Slominski A. Neuroendocrine activity of the melanocyte. *Exp Dermatol*. 2009;18(9):760-763. doi:10.1111/j.1600-0625.2009.00892.x
116. Choi HI, Sohn KC, Hong DK, et al. Melanosome uptake is associated with the proliferation and differentiation of keratinocytes. *Arch Dermatol Res*. 2014;306(1):59-66. doi:10.1007/s00403-013-1422-x
117. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. *Physiol Rev*. 2000;80(3):979-1020. doi:10.1152/physrev.2000.80.3.979
118. Böhm M, Luger TA, Tobin DJ, García-Borrón JC. Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. *J Invest Dermatol*. 2006;126(9):1966-1975. doi:10.1038/sj.jid.5700421
119. Chakraborty AK, Funasaka Y, Slominski A, et al. UV light and MSH receptors. *Ann N Y Acad Sci*. 1999;885:100-116. doi:10.1111/j.1749-6632.1999.tb08668.x
120. Domingues L, Hurbain I, Gilles-Marsens F, et al. Coupling of melanocyte signaling and mechanics by caveolae is required for human skin pigmentation. *Nat Commun*. 2020;11(1):2988. doi:10.1038/s41467-020-16738-z
121. Grando SA. Cholinergic control of epidermal cohesion. *Exp Dermatol*. 2006;15(4):265-282. doi:10.1111/j.0906-6705.2006.00410.x
122. Grando SA, Pittelkow MR, Schallreuter KU. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical significance. *J Invest Dermatol*. 2006;126(9):1948-1965. doi:10.1038/sj.jid.5700151
123. Li M, Knapp SK, Iden S. Mechanisms of melanocyte polarity and differentiation: what can we learn from other neuroectoderm-derived lineages? *Curr Opin Cell Biol*. 2020;67:99-108. doi:10.1016/j.ceb.2020.09.001
124. Pelle E, Mammone T, Maes D, Frenkel K. Keratinocytes act as a source of reactive oxygen species by transferring hydrogen peroxide to melanocytes. *J Invest Dermatol*. 2005;124(4):793-797. doi:10.1111/j.0022-202X.2005.23661.x
125. Sarkar S, Gaddameedhi S. Solar ultraviolet-induced DNA damage response: melanocytes story in transformation to environmental melanomagenesis. *Environ Mol Mutagen*. 2020;61(7):736-751. doi:10.1002/em.22370
126. Slominski A, Wortsman J, Pisarchik A, et al. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. *FASEB J*. 2001;15(10):1678-1693. doi:10.1096/fj.00-0850rev
127. Slominski A, Paus R. Are L-tyrosine and L-dopa hormone-like bioregulators? *J Theor Biol*. 1990;143(1):123-138. doi:10.1016/s0022-5193(05)80292-9
128. Slominski AT, Zmijewski MA, Zbytek B, et al. Regulated proenkephalin expression in human skin and cultured skin cells. *J Invest Dermatol*. 2011;131(3):613-622. doi:10.1038/jid.2010.376
129. Tobin DJ, Kauser S. Beta-endorphin: the forgotten hair follicle melanotropin. *J Invest Dermatol Symp Proc*. 2005;10(3):212-216. doi:10.1111/j.1087-0024.2005.10108.x
130. Yuan XH, Jin ZH. Paracrine regulation of melanogenesis. *Br J Dermatol*. 2018;178(3):632-639. doi:10.1111/bjd.15651
131. Lee AY. Skin pigmentation abnormalities and their possible relationship with skin aging. *Int J Mol Sci*. 2021;22(7):3727. doi:10.3390/ijms22073727
132. Schallreuter KU, Salem MAEL, Holtz S, Panske A. Basic evidence for epidermal H<sub>2</sub>O<sub>2</sub>/ONOO<sup>-</sup>-mediated oxidation/nitration in segmental vitiligo is supported by repigmentation of skin and eyelashes after reduction of epidermal H<sub>2</sub>O<sub>2</sub> with topical NB-UVB-activated pseudocatalase PC-KUS. *FASEB J*. 2013;27(8):3113-3122. doi:10.1096/fj.12-226779
133. Speeckaert R, Dugardin J, Lambert J, et al. Critical appraisal of the oxidative stress pathway in vitiligo: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol*. 2018;32(7):1089-1098. doi:10.1111/jdv.14792
134. Arck PC, Overall R, Spatz K, et al. Towards a “free radical theory of graying”: melanocyte apoptosis in the aging human hair follicle is an indicator of oxidative stress induced tissue damage. *FASEB J*. 2006;20(9):1567-1569. doi:10.1096/fj.05-4039fje
135. Wood JM, Decker H, Hartmann H, et al. Senile hair graying: H<sub>2</sub>O<sub>2</sub>-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. *FASEB J*. 2009;23(7):2065-2075. doi:10.1096/fj.08-125435
136. Gillbro JM, Marles LK, Hibberts NA, Schallreuter KU. Autocrine catecholamine biosynthesis and the  $\beta$ 2-adrenoceptor signal promote pigmentation in human epidermal melanocytes. *J Invest Dermatol*. 2004;123(2):346-353. doi:10.1111/j.0022-202X.2004.23210.x
137. Schallreuter KU, Wood JM, Lemke R, et al. Production of catecholamines in the human epidermis. *Biochem Biophys Res Commun*. 1992;189(1):72-78. doi:10.1016/0006-291X(92)91527-W
138. Ramot Y, Böhm M, Paus R. Translational neuroendocrinology of human skin: concepts and perspectives. *Trends Mol Med*. 2021;27(1):60-74. doi:10.1016/j.molmed.2020.09.002
139. Houssay AB, Pazo JH, Epper CE. Effects of the pineal gland upon the hair cycles in mice. *J Invest Dermatol*. 1966;47(3):230-234. doi:10.1038/jid.1966.135
140. Rust CC, Meyer RK. Hair color, molt, and testis size in male, short-tailed weasels treated with melatonin. *Science*. 1969;165(3896):921-922. doi:10.1126/science.165.3896.921

141. Allain D, Rougeot J. Induction of autumn moult in mink (*Mustela vison* Peale and Beauvois) with melatonin. *Reprod Nutr Dev*. 1980;20(1A):197-201. doi:10.1051/rnd:19800114
142. Lincoln GA, Ebling FJP. Effect of constant-release implants of melatonin on seasonal cycles in reproduction, prolactin secretion and moulting in rams. *Reproduction*. 1985;73(1):241-253. doi:10.1530/jrf.0.0730241
143. Allain D, Ravault JP, Panaretto BA, Rougeot J. Effects of pinealectomy on photoperiodic control of hair follicle activity in the Limousine Ram: possible relationships with plasma prolactin levels. *J Pineal Res*. 1986;3(1):25-32. doi:10.1111/j.1600-079X.1986.tb00723.x
144. Rose J, Oldfield J, Stormshak F. Apparent role of melatonin and prolactin in initiating winter fur growth in mink. *Gen Comp Endocrinol*. 1987;65(2):212-215. doi:10.1016/0016-6480(87)90168-7
145. Welch RAS, Gurnsey MP, Betteridge K, Mitchell RJ. Goat fibre response to melatonin given in spring in two consecutive years. *Proc N Z Soc Anim*. 1990;50:335-338.
146. Webster JR, Suttie JM, Corson ID. Effects of melatonin implants on reproductive seasonality of male red deer (*Cervus elaphus*). *Reproduction*. 1991;92(1):1-11. doi:10.1530/jrf.0.0920001
147. McClohy E, Foldes A, Hollis D, et al. Effects of pinealectomy on wool growth and wool follicle density in Merino sheep. *J Pineal Res*. 1992;13(3):139-144. doi:10.1111/j.1600-079X.1992.tb00068.x
148. Nixon AJ, Choy VJ, Parry AL, Pearson AJ. Fiber growth initiation in hair follicles of goats treated with melatonin. *J Exp Zool*. 1993;267(1):47-56. doi:10.1002/jez.1402670108
149. Ibraheem M, Galbraith H, Scaife J, Ewen S. Growth of secondary hair follicles of the Cashmere goat in vitro and their response to prolactin and melatonin. *J Anat*. 1994;185(Pt 1):135-142.
150. Paterson AM, Foldes A. Melatonin and farm animals: endogenous rhythms and exogenous applications. *J Pineal Res*. 1994;16(4):167-177. doi:10.1111/j.1600-079X.1994.tb00097.x
151. Nixon AJ, Ashby MG, Saywell DP, Pearson AJ. Seasonal fiber growth cycles of ferrets (*Mustela putorius furo*) and long-term effects of melatonin treatment. *J Exp Zool*. 1995;272(6):435-445. doi:10.1002/jez.1402720605
152. Xiao Y, Forsberg M, Laitinen JT, Valtonen M. Effects of melatonin implants in spring on testicular regression and moulting in adult male raccoon dogs (*Nyctereutes procyonoides*). *Reproduction*. 1995;105(1):9-15. doi:10.1530/jrf.0.1050009
153. Diaz SF, Torres SMF, Nogueira SAF, Gilbert S, Jessen CR. The impact of body site, topical melatonin and brushing on hair regrowth after clipping normal Siberian Husky dogs. *Vet Dermatol*. 2006;17(1):45-50. doi:10.1111/j.1365-3164.2005.00497.x
154. Feng Y, Gun S. Melatonin supplement induced the hair follicle development in offspring rex rabbits. *J Anim Physiol Anim Nutr (Berl)*. 2021;105(1):167-174. doi:10.1111/jpn.13417
155. Liu J, Mu Q, Liu Z, et al. Melatonin regulates the periodic growth of cashmere by upregulating the expression of Wnt10b and  $\beta$ -catenin in inner Mongolia cashmere goats. *Front Genet*. 2021;12:0. doi:10.3389/fgene.2021.665834
156. Fischer TW, Fischer A, Knöll B, Hipler UC, Elsner P. Melatonin in low doses enhances in vitro human hair follicle proliferation and inhibits hair growth in high doses. *Arch Derm Res*. 2000;292:147.
157. Fischer TW, Burmeister G, Schmidt HW, Elsner P. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. *Br J Dermatol*. 2004;150(2):341-345. doi:10.1111/j.1365-2133.2004.05685.x
158. Hatem S, Nasr M, Moftah NH, Ragai MH, Geneidi AS, Elkheshen SA. Clinical cosmeceutical repurposing of melatonin in androgenic alopecia using nanostructured lipid carriers prepared with antioxidant oils. *Expert Opin Drug Delivery*. 2018;15(10):927-935. doi:10.1080/17425247.2018.1517740
159. Clive D, Snell RS. Effect of melatonin on mammalian hair color\*\*from the Department of Anatomy, The New Jersey College of Medicine and Dentistry, Jersey City, N.J. 07304. *J Invest Dermatol*. 1969;53(2):159-162. doi:10.1038/jid.1969.123
160. Hoffmann K. Photoperiodic effects in the Djungarian hamster: one minute of light during darktime mimics influence of long photoperiods on testicular recrudescence, body weight and pelage colour. *Experientia*. 1979;35(11):1529-1530. doi:10.1007/BF01962828
161. Logan A, Weatherhead B. Post-tyrosinase Inhibition of melanogenesis by melatonin in hair follicles in vitro. *J Invest Dermatol*. 1980;74(1):47-50. doi:10.1111/1523-1747.ep12514608
162. Thody AJ, Ridley K, Carter RJ, Lucas AM, Shuster S.  $\alpha$ -MSH and coat color changes in the mouse. *Peptides*. 1984;5(6):1031-1036. doi:10.1016/0196-9781(84)90166-9
163. Küderling I, Cedrini MC, Fraschini F, Spagnesi M. Season-dependent effects of melatonin on testes and fur color in mountain hares (*Lepus timidus* L.). *Experientia*. 1984;40(5):501-502. doi:10.1007/BF01952407
164. Duncan MJ, Goldman BD, Di Pinto MN, Stetson MH. Testicular function and pelage color have different critical day-lengths in the Djungarian hamster, *Phodopus sungorus*. *Endocrinology*. 1985;116(1):424-430. doi:10.1210/endo-116-1-424
165. Lerchl A, Schlatt S. Influence of photoperiod on pineal melatonin synthesis, fur color, body weight, and reproductive function in the female Djungarian hamster, *Phodopus sungorus*. *NEN*. 1993;57(2):359-364. doi:10.1159/000126380
166. Slominski A, Chassalevris N, Mazurkiewicz J, Maurer M, Paus R. Murine skin as a target for melatonin bioregulation. *Exp Dermatol*. 1994;3(1):45-50. doi:10.1111/j.1600-0625.1994.tb00265.x
167. Cichorek M, Wachulska M, Stasiewicz A, Tyminińska A. Skin melanocytes: biology and development. *Postepy Dermatol Alergol*. 2013;30(1):30-41. doi:10.5114/pdia.2013.33376
168. Kim TK, Kleszczynski K, Janjetovic Z, et al. Metabolism of melatonin and biological activity of intermediates of melatoninergic pathway in human skin cells. *FASEB J*. 2013;27(7):2742-2755. doi:10.1096/fj.12-224691
169. Hardeland R. Melatonin in aging and disease—multiple consequences of reduced secretion, options and limits of treatment. *Aging Dis*. 2011;3(2):194-225.



170. Kim TK, Lin Z, Tidwell WJ, Li W, Slominski AT. Melatonin and its metabolites accumulate in the human epidermis in vivo and inhibit proliferation and tyrosinase activity in epidermal melanocytes in vitro. *Mol Cell Endocrinol.* 2015;404:1-8. doi:10.1016/j.mce.2014.07.024
171. Sagan D, Stepniak J, Gesing A, Lewinski A, Karbownik-Lewinska M. Melatonin reverses the enhanced oxidative damage to membrane lipids and improves skin biophysical characteristics in former-smokers—a study in post-menopausal women. *Ann Agric Environ Med.* 2017;24(4):659-666. doi:10.5604/12321966.1235174
172. McElhinney DB, Hoffman SJ, Robinson WA, Ferguson J. Effect of melatonin on human skin color. *J Invest Dermatol.* 1994;102(2):258-259. doi:10.1111/1523-1747.ep12371773
173. Nordlund JJ, Lerner AB. The effects of oral melatonin on skin color and on the release of pituitary hormones. *J Clin Endocrinol Metab.* 1977;45(4):768-774. doi:10.1210/jcem-45-4-768
174. Sun H, Wang X, Chen J, et al. Melatonin treatment improves insulin resistance and pigmentation in obese patients with acanthosis nigricans. *Int J Endocrinol.* 2018;2018:1-7. doi:10.1155/2018/2304746
175. Hamadi SA, Mohammed MM, Aljaf AN, Abdulrazak A. The role of topical and oral melatonin in management of melasma patients. *J Arab Univ Basic Appl Sci.* 2009;8:30-42.
176. Milani M, Puviani M. Anti-aging efficacy of melatonin-based cream: clinical and instrumental skin evaluation. *Cosmetics.* 2018;5(4):60. doi:10.3390/cosmetics5040060
177. Granger C, Brown A, Aladren S, Narda M. Night cream containing melatonin, carnosine and helichrysum italicum extract helps reduce skin reactivity and signs of photo-damage: ex vivo and clinical studies. *Dermatol Ther (Heidelb).* 2020;10(6):1315-1329. doi:10.1007/s13555-020-00443-2
178. Schallreuter KU, Salem MA, Gibbons NC, et al. Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, part 1: epidermal H<sub>2</sub>O<sub>2</sub>/ONOO(-)-mediated stress abrogates tryptophan hydroxylase and dopa decarboxylase activities, leading to low serotonin and melatonin levels. *FASEB J.* 2012;26(6):2457-2470. doi:10.1096/fj.11-197137
179. Kotb El-Sayed MI, Abd El-Ghany AA, Mohamed RR. Neural and endocrinal pathobiochemistry of vitiligo: comparative study for a hypothesized mechanism. *Front Endocrinol (Lausanne).* 2018;9:197. doi:10.3389/fendo.2018.00197
180. Slominski A, Paus R, Bomirski A. Hypothesis: possible role for the melatonin receptor in vitiligo: discussion paper. *J R Soc Med.* 1989;82(9):539-541.
181. Kim TK, Lin Z, Li W, Reiter RJ, Slominski AT. N1-acetyl-5-methoxykynuramine (AMK) is produced in the human epidermis and shows antiproliferative effects. *Endocrinology.* 2015;156(5):1630-1636. doi:10.1210/en.2014-1980
182. Kleszczynski K, Kim TK, Bilska B, et al. Melatonin exerts oncostatic capacity and decreases melanogenesis in human MNT-1 melanoma cells. *J Pineal Res.* 2019;67(4):e12610. doi:10.1111/jpi.12610
183. Sun M, Xie HF, Tang Y, et al. G protein-coupled estrogen receptor enhances melanogenesis via cAMP-protein kinase (PKA) by upregulating microphthalmia-related transcription factor-tyrosinase in melanoma. *J Steroid Biochem Mol Biol.* 2017;165:236-246. doi:10.1016/j.jsbmb.2016.06.012
184. Weatherhead B, Logan A. Interaction of  $\alpha$ -melanocyte-stimulating hormone, melatonin, cyclic AMP and cyclic GMP in the control of melanogenesis in hair follicle melanocytes in vitro. *J Endocrinol.* 1981;90(1):89-96. doi:10.1677/joe.0.0900089
185. Valverde P, Benedito E, Solano F, Oaknin S, Lozano JA, García-Borrón JC. Melatonin antagonizes alpha-melanocyte-stimulating hormone enhancement of melanogenesis in mouse melanoma cells by blocking the hormone-induced accumulation of the c locus tyrosinase. *Eur J Biochem.* 1995;232(1):257-263. doi:10.1111/j.1432-1033.1995.tb20807.x
186. Hardman JA, Tobin DJ, Haslam IS, et al. The peripheral clock regulates human pigmentation. *J Invest Dermatol.* 2015;135(4):1053-1064. doi:10.1038/jid.2014.442
187. Lin X, Meng X, Song Z, Lin J. Nuclear factor erythroid 2-related factor 2 (Nrf2) as a potential therapeutic target for vitiligo. *Arch Biochem Biophys.* 2020;696:108670. doi:10.1016/j.jabb.2020.108670
188. Galano A, Reiter RJ. Melatonin and its metabolites vs oxidative stress: from individual actions to collective protection. *J Pineal Res.* 2018;65(1):e12514. doi:10.1111/jpi.12514
189. Sharafati-Chaleshtori R, Shirzad H, Rafieian-Kopaei M, Soltani A. Melatonin and human mitochondrial diseases. *J Res Med Sci.* 2017;22:2. doi:10.4103/1735-1995.199092
190. Schallreuter KU, Rokos H, Chavan B, et al. Quinones are reduced by 6-tetrahydrobiopterin in human keratinocytes, melanocytes, and melanoma cells. *Free Radic Biol Med.* 2008;44(4):538-546. doi:10.1016/j.freeradbiomed.2007.10.043
191. Tan DX, Manchester LC, Terson MP, Flores LJ, Tamura H, Reiter RJ. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. *J Pineal Res.* 2007;43(4):317-320. doi:10.1111/j.1600-079X.2007.00513.x
192. Trueb R. Oxidative stress in ageing of hair. *Int J Trichol.* 2009;1(1):6-14. doi:10.4103/0974-7753.51923
193. Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From discoveries in ageing research to therapeutics for healthy ageing. *Nature.* 2019;571(7764):183-192. doi:10.1038/s41586-019-1365-2
194. De Tollenaere M, Chapuis E, Auriol P, Auriol D, Scandolera A, Reynaud R. Global repigmentation strategy of grey hair follicles by targeting oxidative stress and stem cells protection. *Applied Sciences.* 2021;11(4):1533. doi:10.3390/app11041533
195. Victorelli S, Lagnado A, Halim J, et al. Senescent human melanocytes drive skin ageing via paracrine telomere dysfunction. *EMBO J.* 2019;38(23):e101982. doi:10.15252/embj.2019101982
196. Haslam IS, Jadkauskaite L, Szabó IL, et al. Oxidative damage control in a human (mini-) organ: Nrf2 activation protects against oxidative stress-induced hair growth inhibition. *Journal of Investigative Dermatology.* 2017;137(2):295-304. doi:10.1016/j.jid.2016.08.035
197. Jiang W, Li S, Chen X, et al. Berberine protects immortalized line of human melanocytes from H<sub>2</sub>O<sub>2</sub>-induced oxidative stress via activation of Nrf2 and Mitf signaling pathway.



- J Dermatol Sci.* 2019;94(1):236-243. doi:10.1016/j.jdermsci.2019.03.007
198. Kurek D, Garinis GA, van Doorninck JH, van der Wees J, Grosveld FG. Transcriptome and phenotypic analysis reveals Gata3-dependent signalling pathways in murine hair follicles. *Development.* 2007;134(2):261-272. doi:10.1242/dev.02721
  199. León J, Escames G, Rodríguez MI, et al. Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. *J Neurochem.* 2006;98(6):2023-2033. doi:10.1111/j.1471-4159.2006.04029.x
  200. Sarti P, Magnifico MC, Altieri F, Mastronicola D, Arese M. New evidence for cross talk between melatonin and mitochondria mediated by a circadian-compatible interaction with nitric oxide. *Int J Mol Sci.* 2013;14(6):11259-11276. doi:10.3390/ijms140611259
  201. Soto-Vega E, Meza I, Ramírez-Rodríguez G, Benitez-King G. Melatonin stimulates calmodulin phosphorylation by protein kinase C. *J Pineal Res.* 2004;37(2):98-106. doi:10.1111/j.1600-079X.2004.00141.x
  202. Emerit I, Filipe P, Freitas J, Vassy J. Protective effect of superoxide dismutase against hair graying in a mouse model. *Photochem Photobiol.* 2004;80(3):579-582. doi:10.1562/0031-8655(2004)080%3C0579:PEOSDA%3E2.0.CO;2
  203. Hollfelder B, Blankenburg G, Wolfram LJ, Höcker H. Chemical and physical properties of pigmented and non-pigmented hair ('grey hair'). *Int J Cosmet Sci.* 1995;17(2):87-89. doi:10.1111/j.1467-2494.1995.tb00112.x
  204. Seiberg M. Age-induced hair graying and oxidative stress. In: Farage MA, Miller KW, Maibach HI, eds. *Textbook of Aging Skin.* Berlin Heidelberg: Springer; 2015:1-14. doi:10.1007/978-3-642-27814-3\_117-1
  205. Bertazzo A, Biasiolo M, Costa CVL, Cardin de Stefani E, Allegrì G. Tryptophan in human hair: correlation with pigmentation. *Farmaco [Prat].* 2000;55(8):521-525. doi:10.1016/S0014-827X(00)00038-0
  206. Nahhas AF, Abdel-Malek ZA, Kohli I, Braunberger TL, Lim HW, Hamzavi IH. The potential role of antioxidants in mitigating skin hyperpigmentation resulting from ultraviolet and visible light-induced oxidative stress. *Photodermatol Photoimmunol Photomed.* 2019;35(6):420-428. doi:10.1111/phpp.12423
  207. Poljšak B, Dahmane R. Free radicals and extrinsic skin aging. *Dermatol Res Pract.* 2012;2012:135206. doi:10.1155/2012/135206
  208. Chaiprasongsuk A, Janjetovic Z, Kim TK, et al. Protective effects of novel derivatives of vitamin D3 and lumisterol against UVB-induced damage in human keratinocytes involve activation of Nrf2 and p53 defense mechanisms. *Redox Biol.* 2019;24:101206. doi:10.1016/j.redox.2019.101206
  209. Chaiprasongsuk A, Janjetovic Z, Kim TK, et al. Hydroxylumisterols, photoproducts of pre-vitamin D3, protect human keratinocytes against UVB-induced damage. *IJMS.* 2020;21(24):9374. doi:10.3390/ijms21249374
  210. Slominski AT, Chaiprasongsuk A, Janjetovic Z, et al. Photoprotective properties of Vitamin D and lumisterol hydroxyderivatives. *Cell Biochem Biophys.* 2020;78(2):165-180. doi:10.1007/s12013-020-00913-6
  211. Slominski AT, Janjetovic Z, Kim TK, et al. Novel non-calcemic secosteroids that are produced by human epidermal keratinocytes protect against solar radiation. *J Steroid Biochem Mol Biol.* 2015;148:52-63. doi:10.1016/j.jsbmb.2015.01.014
  212. Rosenberg AM, Rausser S, Ren J, et al. Quantitative mapping of human hair greying and reversal in relation to life stress. *eLife.* 2021;10:e67437. doi:10.7554/eLife.67437
  213. Stout R, Birch-Machin M. Mitochondria's role in skin ageing. *Biology.* 2019;8(2):29. doi:10.3390/biology8020029
  214. van der Blik AM, Sedensky MM, Morgan PG. Cell biology of the mitochondrion. *Genetics.* 2017;207(3):843-871. doi:10.1534/genetics.117.300262
  215. Venegas C, García JA, Escames G, et al. Extrpineal melatonin: analysis of its subcellular distribution and daily fluctuations. *J Pineal Res.* 2012;52(2):217-227. doi:10.1111/j.1600-079X.2011.00931.x
  216. Huo X, Wang C, Yu Z, et al. Human transporters, PEPT1/2, facilitate melatonin transportation into mitochondria of cancer cells: an implication of the therapeutic potential. *J Pineal Res.* 2017;62(4):e12390. doi:10.1111/jpi.12390
  217. Suofu Y, Li W, Jean-Alphonse FG, et al. Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release. *Proc Natl Acad Sci U S A.* 2017;114(38):E7997-E8006. doi:10.1073/pnas.1705768114
  218. Reiter RJ, Tan DX, Rosales-Corral S, Galano A, Jou MJ, Acuna-Castroviejo D. Melatonin mitigates mitochondrial meltdown: interactions with SIRT3. *Int J Mol Sci.* 2018;19(8). doi:10.3390/ijms19082439
  219. Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Changes in the mitochondrial permeability transition pore in aging and age-associated diseases. *Mech Ageing Dev.* 2013;134(1):1-9. doi:10.1016/j.mad.2012.12.006
  220. Annapoorna S, Aguilera-Aguirre L, Singh KK. Mitochondria in skin health, aging, and disease. *Cell Death Dis.* 2020;11(6):444. doi:10.1038/s41419-020-2649-z
  221. Fischer TW, Zmijewski MA, Wortsman J, Slominski A. Melatonin maintains mitochondrial membrane potential and attenuates activation of initiator (casp-9) and effector caspases (casp-3/casp-7) and PARP in UVR-exposed HaCaT keratinocytes. *J Pineal Res.* 2008;44(4):397-407. doi:10.1111/j.1600-079X.2007.00542.x
  222. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. *J Pathol.* 2010;221(1):3-12. doi:10.1002/path.2697
  223. Scherz-Shouval R, Elazar Z. Regulation of autophagy by ROS: physiology and pathology. *Trends Biochem Sci.* 2011;36(1):30-38. doi:10.1016/j.tibs.2010.07.007
  224. Coto-Montes A, Boga JA, Rosales-Corral S, Fuentes-Broto L, Tan DX, Reiter RJ. Role of melatonin in the regulation of autophagy and mitophagy: a review. *Mol Cell Endocrinol.* 2012;361(1):12-23. doi:10.1016/j.mce.2012.04.009
  225. He Y, Li S, Zhang W, et al. Dysregulated autophagy increased melanocyte sensitivity to H2O2-induced oxidative stress in vitiligo. *Sci Rep.* 2017;7(1):42394. doi:10.1038/srep42394
  226. Jeong D, Qomaladewi NP, Lee J, Park SH, Cho JY. The role of autophagy in skin fibroblasts, keratinocytes, melanocytes, and epidermal stem cells. *J Invest Dermatol.* 2020;140(9):1691-1697. doi:10.1016/j.jid.2019.11.023

227. Bomirski A, Wrzółkowska T, Arendarczyk M, et al. Pathology and ultrastructural characteristics of a hypomelanotic variant of transplantable hamster melanoma with elevated tyrosinase activity. *J Invest Dermatol.* 1987;89(5):469-473. doi:10.1111/1523-1747.ep12460928
228. Bomirski A, Słominski A, Bigda J. The natural history of a family of transplantable melanomas in hamsters. *Cancer Metastasis Rev.* 1988;7(2):95-118. doi:10.1007/BF00046481
229. Murase D, Hachiya A, Takano K, et al. Autophagy has a significant role in determining skin color by regulating melanosome degradation in keratinocytes. *J Invest Dermatol.* 2013;133(10):2416-2424. doi:10.1038/jid.2013.165
230. Zhu W, Zhao Z, Cheng B. The role of autophagy in skin pigmentation. *Eur J Dermatol.* 2020;30(6):655-662. doi:10.1684/ejcd.2020.3930
231. Boga JA, Caballero B, Potes Y, et al. Therapeutic potential of melatonin related to its role as an autophagy regulator: a review. *J Pineal Res.* 2019;66(1):e12534. doi:10.1111/jpi.12534
232. Jenwitheesuk A, Nopparat C, Mukda S, Wongchitrat P, Govitrapong P. Melatonin regulates aging and neurodegeneration through energy metabolism, epigenetics, autophagy and circadian rhythm pathways. *Int J Mol Sci.* 2014;15(9):16848-16884. doi:10.3390/ijms150916848
233. Parodi C, Hardman JA, Allavena G, et al. Autophagy is essential for maintaining the growth of a human (mini-)organ: evidence from scalp hair follicle organ culture. *PLOS Biol.* 2018;16(3):e2002864. doi:10.1371/journal.pbio.2002864
234. Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. *Science.* 2011;333(6046):1109-1112. doi:10.1126/science.1201940
235. Yessenkyzy A, Saliev T, Zhanaliyeva M, et al. Polyphenols as caloric-restriction mimetics and autophagy inducers in aging research. *Nutrients.* 2020;12(5):E1344. doi:10.3390/nu12051344
236. Lee IH, Cao L, Mostoslavsky R, et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. *Proc Natl Acad Sci U S A.* 2008;105(9):3374-3379. doi:10.1073/pnas.0712145105
237. Xu C, Wang L, Fozouni P, et al. SIRT1 is downregulated by autophagy in senescence and ageing. *Nat Cell Biol.* 2020;22(10):1170-1179. doi:10.1038/s41556-020-00579-5
238. Bocheva G, Slominski RM, Janjetovic Z, et al. Protective role of melatonin and its metabolites in skin aging. *Int J Mol Sci.* 2022;23:1238. doi:10.3390/ijms23031238
239. Stefan J, Kim TK, Schedel F, et al. Differential and overlapping effects of melatonin and its metabolites on keratinocyte function: bioinformatics and metabolic analyses. *Antioxidants (Basel).* 2021;10(4). doi:10.3390/antiox10040618
240. Benedusi M, Frigato E, Beltramello M, Bertolucci C, Valacchi G. Circadian clock as possible protective mechanism to pollution induced keratinocytes damage. *Mech Ageing Dev.* 2018;172:13-20. doi:10.1016/j.mad.2017.08.017
241. Reppert SM, Weaver DR. Molecular analysis of mammalian circadian rhythms. *Annu Rev Physiol.* 2001;63(1):647-676. doi:10.1146/annurev.physiol.63.1.647
242. Vitaterna MH, Selby CP, Todo T, et al. Differential regulation of mammalian Period genes and circadian rhythmicity by cryptochromes 1 and 2. *Proc Natl Acad Sci.* 1999;96(21):12114-12119. doi:10.1073/pnas.96.21.12114
243. Sarkar S, Porter KI, Dakup PP, et al. Circadian clock protein BMAL1 regulates melanogenesis through MITF in melanoma cells. *Pigment Cell Melanoma Res.* 2021;34(5):955-965. doi:10.1111/pcmr.12998
244. Boutin JA, Witt-Enderby PA, Sottriffer C, Zlotos DP. Melatonin receptor ligands: a pharmaco-chemical perspective. *J Pineal Res.* 2020;69(3):e12672. doi:10.1111/jpi.12672
245. Bora NS, Mazumder B, Mandal S, et al. Amelioration of UV radiation-induced photoaging by a combinational sunscreen formulation via aversion of oxidative collagen degradation and promotion of TGF- $\beta$ -Smad-mediated collagen production. *Eur J Pharm Sci.* 2019;127:261-275. doi:10.1016/j.ejps.2018.11.004
246. Guan LL, Lim HW, Mohammad TF. Sunscreens and photoaging: a review of current literature. *Am J Clin Dermatol.* 2021;22:819-828. doi:10.1007/s40257-021-00632-5
247. Bocheva G, Slominski RM, Slominski AT. Neuroendocrine aspects of skin aging. *Int J Mol Sci.* 2019;20(11):E2798. doi:10.3390/ijms20112798
248. Rusanova I, Martínez-Ruiz L, Florido J, et al. Protective effects of melatonin on the skin: future perspectives. *Int J Mol Sci.* 2019;20(19):4948. doi:10.3390/ijms20194948
249. Scheuer C, Pommergaard HC, Rosenberg J, Gögenur I. Melatonin's protective effect against UV radiation: a systematic review of clinical and experimental studies. *Photodermatol Photoimmunol Photomed.* 2014;30(4):180-188. doi:10.1111/phpp.12080
250. Fisher GJ, Kang S, Varani J, et al. Mechanisms of photoaging and chronological skin aging. *Arch Dermatol.* 2002;138(11):1462-1470. doi:10.1001/archderm.138.11.1462
251. Kleszczynski K, Fischer TW. Melatonin and human skin aging. *Dermato-Endocrinology.* 2012;4(3):245-252. doi:10.4161/derm.22344
252. Fernández A, Ordóñez R, Reiter RJ, González-Gallego J, Mauriz JL. Melatonin and endoplasmic reticulum stress: relation to autophagy and apoptosis. *J Pineal Res.* 2015;59(3):292-307. doi:10.1111/jpi.12264
253. Scheuer C, Pommergaard HC, Rosenberg J, Gögenur I. Dose dependent sun protective effect of topical melatonin: a randomized, placebo-controlled, double-blind study. *J Dermatol Sci.* 2016;84(2):178-185. doi:10.1016/j.jdermsci.2016.08.007
254. Yang F, Yang L, Wataya-Kaneda M, et al. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex. *J Dermatol Sci.* 2018;89(2):155-164. doi:10.1016/j.jdermsci.2017.11.002
255. Scheibye-Knudsen M, Ramamoorthy M, Sykora P, et al. Cockayne syndrome group B protein prevents the accumulation of damaged mitochondria by promoting mitochondrial autophagy. *J Exp Med.* 2012;209(4):855-869. doi:10.1084/jem.20111721
256. Fischer TW, Greif C, Fluhr JW, Wigger-Alberti W, Elsner P. Percutaneous penetration of topically applied melatonin in a cream and an alcoholic solution. *Skin Pharmacol Physiol.* 2004;17(4):190-194. doi:10.1159/000078822
257. Bora NS, Mazumder B, Mandal S, et al. Protective effect of a topical sunscreen formulation fortified with melatonin against UV-induced photodermatitis: an immunomodulatory effect via NF- $\kappa$ B suppression. *Immunopharmacol Immunotoxicol.* 2019;41(1):130-139. doi:10.1080/08923973.2019.1566358
258. Chuffa L, Seiva FRF, Novais AA, et al. Melatonin-loaded nanocarriers: new horizons for therapeutic applications. *Molecules.* 2021;26(12):3562. doi:10.3390/molecules26123562

259. Shukla R, Tiwari G, Tiwari R, Rai AK. Formulation and evaluation of the topical ethosomal gel of melatonin to prevent UV radiation. *J Cosmet Dermatol*. 2020;19(8):2093-2104. doi:10.1111/jocd.13251
260. Bertolini M, Ramot Y, Gherardini J, et al. Theophylline exerts complex anti-ageing and anti-cytotoxicity effects in human skin *ex vivo*. *Int J Cosmet Sci*. 2020;42(1):79-88. doi:10.1111/ics.12589
261. Jeayeng S, Wongkajornsilp A, Slominski AT, Jirawatnotai S, Sampattavanich S, Panich U. Nrf2 in keratinocytes modulates UVB-induced DNA damage and apoptosis in melanocytes through MAPK signaling. *Free Radic Biol Med*. 2017;108:918-928. doi:10.1016/j.freeradbiomed.2017.05.009

## SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

**How to cite this article:** Sevilla A, Chéret J, Slominski RM, Slominski AT, Paus R. Revisiting the role of melatonin in human melanocyte physiology: a skin context perspective. *J Pineal Res*. 2022;72:e12790. doi:10.1111/jpi.12790